TWI759576B - 抗體protac複合體 - Google Patents
抗體protac複合體 Download PDFInfo
- Publication number
- TWI759576B TWI759576B TW108100998A TW108100998A TWI759576B TW I759576 B TWI759576 B TW I759576B TW 108100998 A TW108100998 A TW 108100998A TW 108100998 A TW108100998 A TW 108100998A TW I759576 B TWI759576 B TW I759576B
- Authority
- TW
- Taiwan
- Prior art keywords
- protein
- protac
- antibody
- cancer
- immune complex
- Prior art date
Links
- 108010026668 snake venom protein C activator Proteins 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 84
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 82
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 claims abstract description 32
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 claims abstract description 32
- 230000027455 binding Effects 0.000 claims abstract description 31
- 239000003446 ligand Substances 0.000 claims abstract description 25
- 239000012634 fragment Substances 0.000 claims abstract description 7
- 102000040945 Transcription factor Human genes 0.000 claims abstract description 5
- 108091023040 Transcription factor Proteins 0.000 claims abstract description 5
- 102000006575 G-Protein-Coupled Receptor Kinases Human genes 0.000 claims abstract description 3
- 108010008959 G-Protein-Coupled Receptor Kinases Proteins 0.000 claims abstract description 3
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 claims abstract 2
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims description 40
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 16
- 239000000427 antigen Substances 0.000 claims description 15
- 108091007433 antigens Proteins 0.000 claims description 15
- 102000036639 antigens Human genes 0.000 claims description 15
- 201000011510 cancer Diseases 0.000 claims description 13
- 239000003112 inhibitor Substances 0.000 claims description 13
- 229960000575 trastuzumab Drugs 0.000 claims description 13
- 206010006187 Breast cancer Diseases 0.000 claims description 12
- 208000026310 Breast neoplasm Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 230000008685 targeting Effects 0.000 claims description 12
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 10
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 8
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 claims description 7
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 claims description 7
- 102000003984 Aryl Hydrocarbon Receptors Human genes 0.000 claims description 4
- 108090000448 Aryl Hydrocarbon Receptors Proteins 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 102100037024 E3 ubiquitin-protein ligase XIAP Human genes 0.000 claims description 3
- 101710113864 Heat shock protein 90 Proteins 0.000 claims description 3
- 108700031544 X-Linked Inhibitor of Apoptosis Proteins 0.000 claims description 3
- 229960000548 alemtuzumab Drugs 0.000 claims description 3
- 229960000455 brentuximab vedotin Drugs 0.000 claims description 3
- 229960005395 cetuximab Drugs 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 229960000578 gemtuzumab Drugs 0.000 claims description 3
- 230000001506 immunosuppresive effect Effects 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 229960004641 rituximab Drugs 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 102000000717 Lysine methyltransferases Human genes 0.000 claims description 2
- 108050008120 Lysine methyltransferases Proteins 0.000 claims description 2
- 239000012819 MDM2-Inhibitor Substances 0.000 claims description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims description 2
- 108091000080 Phosphotransferase Proteins 0.000 claims description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims description 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims description 2
- 102000053842 human bromodomain and extra-terminal domain Human genes 0.000 claims description 2
- 108700009340 human bromodomain and extra-terminal domain Proteins 0.000 claims description 2
- 229950010203 nimotuzumab Drugs 0.000 claims description 2
- 102000020233 phosphotransferase Human genes 0.000 claims description 2
- 229950001460 sacituzumab Drugs 0.000 claims description 2
- 102100040277 Acyl-protein thioesterase 2 Human genes 0.000 claims 2
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims 2
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims 2
- 102000015694 estrogen receptors Human genes 0.000 claims 2
- 108010038795 estrogen receptors Proteins 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 101710132083 Acyl-protein thioesterase 2 Proteins 0.000 claims 1
- 102100030346 Antigen peptide transporter 1 Human genes 0.000 claims 1
- 108050009514 Antigen peptide transporter 1 Proteins 0.000 claims 1
- 108050001544 Antigen peptide transporter 2 Proteins 0.000 claims 1
- 101100279855 Arabidopsis thaliana EPFL5 gene Proteins 0.000 claims 1
- 102100020998 Aspartate beta-hydroxylase domain-containing protein 1 Human genes 0.000 claims 1
- 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 claims 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 1
- 102100027052 Bone morphogenetic protein receptor type-1B Human genes 0.000 claims 1
- 108010085074 Brevican Proteins 0.000 claims 1
- 102100032312 Brevican core protein Human genes 0.000 claims 1
- 102100026094 C-type lectin domain family 12 member A Human genes 0.000 claims 1
- 102100024220 CD180 antigen Human genes 0.000 claims 1
- 101150031358 COLEC10 gene Proteins 0.000 claims 1
- 102100032768 Complement receptor type 2 Human genes 0.000 claims 1
- 102100036466 Delta-like protein 3 Human genes 0.000 claims 1
- 102100031517 Fc receptor-like protein 1 Human genes 0.000 claims 1
- 101710120224 Fc receptor-like protein 1 Proteins 0.000 claims 1
- 102100031511 Fc receptor-like protein 2 Human genes 0.000 claims 1
- 102100031507 Fc receptor-like protein 5 Human genes 0.000 claims 1
- 108010002459 HIV Integrase Proteins 0.000 claims 1
- 108010010369 HIV Protease Proteins 0.000 claims 1
- 102100031546 HLA class II histocompatibility antigen, DO beta chain Human genes 0.000 claims 1
- 101000783987 Homo sapiens Aspartate beta-hydroxylase domain-containing protein 1 Proteins 0.000 claims 1
- 101000934359 Homo sapiens B-cell differentiation antigen CD72 Proteins 0.000 claims 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 1
- 101000984546 Homo sapiens Bone morphogenetic protein receptor type-1B Proteins 0.000 claims 1
- 101000980829 Homo sapiens CD180 antigen Proteins 0.000 claims 1
- 101100496086 Homo sapiens CLEC12A gene Proteins 0.000 claims 1
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 claims 1
- 101000928513 Homo sapiens Delta-like protein 3 Proteins 0.000 claims 1
- 101000846911 Homo sapiens Fc receptor-like protein 2 Proteins 0.000 claims 1
- 101000846908 Homo sapiens Fc receptor-like protein 5 Proteins 0.000 claims 1
- 101000866281 Homo sapiens HLA class II histocompatibility antigen, DO beta chain Proteins 0.000 claims 1
- 101001091205 Homo sapiens KiSS-1 receptor Proteins 0.000 claims 1
- 101001063456 Homo sapiens Leucine-rich repeat-containing G-protein coupled receptor 5 Proteins 0.000 claims 1
- 101001065550 Homo sapiens Lymphocyte antigen 6K Proteins 0.000 claims 1
- 101000620359 Homo sapiens Melanocyte protein PMEL Proteins 0.000 claims 1
- 101000628547 Homo sapiens Metalloreductase STEAP1 Proteins 0.000 claims 1
- 101000628535 Homo sapiens Metalloreductase STEAP2 Proteins 0.000 claims 1
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 1
- 101000829779 Homo sapiens Probable G-protein coupled receptor 19 Proteins 0.000 claims 1
- 101000825475 Homo sapiens Protein shisa-2 homolog Proteins 0.000 claims 1
- 101000853730 Homo sapiens RING finger and transmembrane domain-containing protein 2 Proteins 0.000 claims 1
- 101000713169 Homo sapiens Solute carrier family 52, riboflavin transporter, member 2 Proteins 0.000 claims 1
- 101000835745 Homo sapiens Teratocarcinoma-derived growth factor 1 Proteins 0.000 claims 1
- 101000834937 Homo sapiens Tomoregulin-1 Proteins 0.000 claims 1
- 101000834948 Homo sapiens Tomoregulin-2 Proteins 0.000 claims 1
- 101000920026 Homo sapiens Tumor necrosis factor receptor superfamily member EDAR Proteins 0.000 claims 1
- 102100034845 KiSS-1 receptor Human genes 0.000 claims 1
- 102100031036 Leucine-rich repeat-containing G-protein coupled receptor 5 Human genes 0.000 claims 1
- 102100032129 Lymphocyte antigen 6K Human genes 0.000 claims 1
- 102100022430 Melanocyte protein PMEL Human genes 0.000 claims 1
- 102100026712 Metalloreductase STEAP1 Human genes 0.000 claims 1
- 102100026711 Metalloreductase STEAP2 Human genes 0.000 claims 1
- 102100023123 Mucin-16 Human genes 0.000 claims 1
- 101100042271 Mus musculus Sema3b gene Proteins 0.000 claims 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 1
- 102100037603 P2X purinoceptor 5 Human genes 0.000 claims 1
- 101710189969 P2X purinoceptor 5 Proteins 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 102100023417 Probable G-protein coupled receptor 19 Human genes 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- 102100022938 Protein shisa-2 homolog Human genes 0.000 claims 1
- 102100035928 RING finger and transmembrane domain-containing protein 2 Human genes 0.000 claims 1
- 108091005682 Receptor kinases Proteins 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 102100036862 Solute carrier family 52, riboflavin transporter, member 2 Human genes 0.000 claims 1
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 claims 1
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 claims 1
- 102100026404 Teratocarcinoma-derived growth factor 1 Human genes 0.000 claims 1
- 102100026159 Tomoregulin-1 Human genes 0.000 claims 1
- 102100026160 Tomoregulin-2 Human genes 0.000 claims 1
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 claims 1
- 101710178300 Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 claims 1
- 102100030810 Tumor necrosis factor receptor superfamily member EDAR Human genes 0.000 claims 1
- 102000003425 Tyrosinase Human genes 0.000 claims 1
- 108060008724 Tyrosinase Proteins 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 102000001307 androgen receptors Human genes 0.000 claims 1
- 108010080146 androgen receptors Proteins 0.000 claims 1
- 201000000493 colon squamous cell carcinoma Diseases 0.000 claims 1
- 229940127276 delta-like ligand 3 Drugs 0.000 claims 1
- 239000002532 enzyme inhibitor Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 208000012972 squamous cell carcinoma of colon Diseases 0.000 claims 1
- 150000007970 thio esters Chemical class 0.000 claims 1
- 102000004217 thyroid hormone receptors Human genes 0.000 claims 1
- 108090000721 thyroid hormone receptors Proteins 0.000 claims 1
- 239000011230 binding agent Substances 0.000 abstract description 7
- 102000016914 ras Proteins Human genes 0.000 abstract description 4
- 101150040459 RAS gene Proteins 0.000 abstract description 3
- 101150076031 RAS1 gene Proteins 0.000 abstract description 3
- 229940127121 immunoconjugate Drugs 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 32
- -1 E2F Proteins 0.000 description 19
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 14
- 125000005647 linker group Chemical group 0.000 description 14
- 239000011541 reaction mixture Substances 0.000 description 14
- RWLOGRLTDKDANT-TYIYNAFKSA-N 2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaen-9-yl]-N-[4-[2-[2-[2-[2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]ethoxy]ethoxy]ethoxy]ethoxy]phenyl]acetamide Chemical compound CC1=NN=C2[C@H](CC(=O)NC3=CC=C(OCCOCCOCCOCCNC4=C5C(=O)N(C6CCC(=O)NC6=O)C(=O)C5=CC=C4)C=C3)N=C(C3=C(SC(C)=C3C)N12)C1=CC=C(Cl)C=C1 RWLOGRLTDKDANT-TYIYNAFKSA-N 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 238000011865 proteolysis targeting chimera technique Methods 0.000 description 12
- 229940124823 proteolysis targeting chimeric molecule Drugs 0.000 description 12
- 230000008901 benefit Effects 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 230000015556 catabolic process Effects 0.000 description 10
- 229940125898 compound 5 Drugs 0.000 description 10
- 238000006731 degradation reaction Methods 0.000 description 10
- 150000003384 small molecules Chemical class 0.000 description 10
- GNMUEVRJHCWKTO-FQEVSTJZSA-N 6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, 4-(4-chlorophenyl)-n-(4-hydroxyphenyl)-2,3,9-trimethyl-, (6s)- Chemical compound C([C@@H]1N=C(C2=C(N3C(C)=NN=C31)SC(=C2C)C)C=1C=CC(Cl)=CC=1)C(=O)NC1=CC=C(O)C=C1 GNMUEVRJHCWKTO-FQEVSTJZSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- 238000010798 ubiquitination Methods 0.000 description 9
- 230000034512 ubiquitination Effects 0.000 description 9
- 229940049595 antibody-drug conjugate Drugs 0.000 description 8
- 230000002490 cerebral effect Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 7
- 239000003960 organic solvent Substances 0.000 description 7
- 230000017854 proteolysis Effects 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 229940124597 therapeutic agent Drugs 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 102000001805 Bromodomains Human genes 0.000 description 6
- 108050009021 Bromodomains Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 125000000524 functional group Chemical group 0.000 description 6
- 230000009437 off-target effect Effects 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 108010016626 Dipeptides Proteins 0.000 description 5
- 102000003960 Ligases Human genes 0.000 description 5
- 108090000364 Ligases Proteins 0.000 description 5
- 108091008611 Protein Kinase B Proteins 0.000 description 5
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 5
- 229950000080 birabresib Drugs 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 229960002173 citrulline Drugs 0.000 description 5
- 230000021615 conjugation Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 108091052242 Bromo- and Extra-Terminal domain (BET) family Proteins 0.000 description 4
- 102100033641 Bromodomain-containing protein 2 Human genes 0.000 description 4
- 102100033642 Bromodomain-containing protein 3 Human genes 0.000 description 4
- 101000871850 Homo sapiens Bromodomain-containing protein 2 Proteins 0.000 description 4
- 101000871851 Homo sapiens Bromodomain-containing protein 3 Proteins 0.000 description 4
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 4
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 3
- 101100239628 Danio rerio myca gene Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102100040341 E3 ubiquitin-protein ligase UBR5 Human genes 0.000 description 3
- 102100038576 F-box/WD repeat-containing protein 1A Human genes 0.000 description 3
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 description 3
- 102000003956 Fibroblast growth factor 8 Human genes 0.000 description 3
- 101000671838 Homo sapiens E3 ubiquitin-protein ligase UBR5 Proteins 0.000 description 3
- 101001030691 Homo sapiens F-box/WD repeat-containing protein 1A Proteins 0.000 description 3
- 108060006678 I-kappa-B kinase Proteins 0.000 description 3
- 102000001284 I-kappa-B kinase Human genes 0.000 description 3
- 101150039798 MYC gene Proteins 0.000 description 3
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 3
- 102100030434 Ubiquitin-protein ligase E3A Human genes 0.000 description 3
- 101100459258 Xenopus laevis myc-a gene Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 229940125644 antibody drug Drugs 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 229960003330 pentetic acid Drugs 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 229960000688 pomalidomide Drugs 0.000 description 3
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 2
- 102100021662 Baculoviral IAP repeat-containing protein 3 Human genes 0.000 description 2
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 2
- 102100028907 Cullin-4A Human genes 0.000 description 2
- 101710159242 Cullin-4A Proteins 0.000 description 2
- 102100032045 E3 ubiquitin-protein ligase AMFR Human genes 0.000 description 2
- 102100031918 E3 ubiquitin-protein ligase NEDD4 Human genes 0.000 description 2
- 102100034214 E3 ubiquitin-protein ligase RNF128 Human genes 0.000 description 2
- 102100039503 E3 ubiquitin-protein ligase RNF31 Human genes 0.000 description 2
- 102100038662 E3 ubiquitin-protein ligase SMURF2 Human genes 0.000 description 2
- 102100025014 E3 ubiquitin-protein ligase TRIM63 Human genes 0.000 description 2
- 108010003751 Elongin Proteins 0.000 description 2
- 102000004662 Elongin Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004864 Fibroblast growth factor 10 Human genes 0.000 description 2
- 108090001047 Fibroblast growth factor 10 Proteins 0.000 description 2
- 102100037813 Focal adhesion kinase 1 Human genes 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 102000006947 Histones Human genes 0.000 description 2
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 2
- 101000776154 Homo sapiens E3 ubiquitin-protein ligase AMFR Proteins 0.000 description 2
- 101000636713 Homo sapiens E3 ubiquitin-protein ligase NEDD4 Proteins 0.000 description 2
- 101000711673 Homo sapiens E3 ubiquitin-protein ligase RNF128 Proteins 0.000 description 2
- 101000664952 Homo sapiens E3 ubiquitin-protein ligase SMURF2 Proteins 0.000 description 2
- 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 description 2
- 101000891649 Homo sapiens Transcription elongation factor A protein-like 1 Proteins 0.000 description 2
- 101000772888 Homo sapiens Ubiquitin-protein ligase E3A Proteins 0.000 description 2
- 101710177504 Kit ligand Proteins 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 229940124647 MEK inhibitor Drugs 0.000 description 2
- 101150010110 Map3k8 gene Proteins 0.000 description 2
- 102100026888 Mitogen-activated protein kinase kinase kinase 7 Human genes 0.000 description 2
- 102100026907 Mitogen-activated protein kinase kinase kinase 8 Human genes 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 102100032783 Protein cereblon Human genes 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 101150001535 SRC gene Proteins 0.000 description 2
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 2
- 102000004399 TNF receptor-associated factor 3 Human genes 0.000 description 2
- 108090000922 TNF receptor-associated factor 3 Proteins 0.000 description 2
- 102000003714 TNF receptor-associated factor 6 Human genes 0.000 description 2
- 108090000009 TNF receptor-associated factor 6 Proteins 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 2
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 2
- 102000044159 Ubiquitin Human genes 0.000 description 2
- 108090000848 Ubiquitin Proteins 0.000 description 2
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000005441 aurora Substances 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229960004942 lenalidomide Drugs 0.000 description 2
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 2
- 230000002132 lysosomal effect Effects 0.000 description 2
- 102000045222 parkin Human genes 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 230000013878 renal filtration Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- 108091008743 testicular receptors 4 Proteins 0.000 description 2
- 229960003433 thalidomide Drugs 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 2
- 229950009811 ubenimex Drugs 0.000 description 2
- ADHFFUOAOLWHGU-JPDUFPOXSA-N (2s)-2-[[(2s)-4-amino-2-[[(2s,3r)-2-[[(2s)-2-[[(2s)-2-[[(2s,3s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]hexanoyl]a Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@@H](N)CO)C(C)C)C1=CC=CC=C1 ADHFFUOAOLWHGU-JPDUFPOXSA-N 0.000 description 1
- VYMPLPIFKRHAAC-UHFFFAOYSA-N 1,2-ethanedithiol Chemical compound SCCS VYMPLPIFKRHAAC-UHFFFAOYSA-N 0.000 description 1
- FOZVXADQAHVUSV-UHFFFAOYSA-N 1-bromo-2-(2-bromoethoxy)ethane Chemical compound BrCCOCCBr FOZVXADQAHVUSV-UHFFFAOYSA-N 0.000 description 1
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 description 1
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
- QEDXSHCYPROEOK-UHFFFAOYSA-N 3-phosphanylpropanoic acid Chemical compound OC(=O)CCP QEDXSHCYPROEOK-UHFFFAOYSA-N 0.000 description 1
- 102100037263 3-phosphoinositide-dependent protein kinase 1 Human genes 0.000 description 1
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 1
- LQILVUYCDHSGEU-UHFFFAOYSA-N 4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexane-1-carboxylic acid Chemical compound C1CC(C(=O)O)CCC1CN1C(=O)C=CC1=O LQILVUYCDHSGEU-UHFFFAOYSA-N 0.000 description 1
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 101150019464 ARAF gene Proteins 0.000 description 1
- 101000783817 Agaricus bisporus lectin Proteins 0.000 description 1
- 108010031677 Anaphase-Promoting Complex-Cyclosome Proteins 0.000 description 1
- 102000005446 Anaphase-Promoting Complex-Cyclosome Human genes 0.000 description 1
- 102100022014 Angiopoietin-1 receptor Human genes 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 102100034691 Astrocytic phosphoprotein PEA-15 Human genes 0.000 description 1
- 102100035029 Ataxin-1 Human genes 0.000 description 1
- 108010032963 Ataxin-1 Proteins 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108010014380 Autophagy-Related Protein-1 Homolog Proteins 0.000 description 1
- 108091007065 BIRCs Proteins 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 102000036365 BRCA1 Human genes 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 108700003785 Baculoviral IAP Repeat-Containing 3 Proteins 0.000 description 1
- 102100021677 Baculoviral IAP repeat-containing protein 2 Human genes 0.000 description 1
- 101710177962 Baculoviral IAP repeat-containing protein 3 Proteins 0.000 description 1
- 102100036597 Basement membrane-specific heparan sulfate proteoglycan core protein Human genes 0.000 description 1
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 description 1
- VGGGPCQERPFHOB-UHFFFAOYSA-N Bestatin Natural products CC(C)CC(C(O)=O)NC(=O)C(O)C(N)CC1=CC=CC=C1 VGGGPCQERPFHOB-UHFFFAOYSA-N 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 102100029894 Bromodomain testis-specific protein Human genes 0.000 description 1
- 238000007125 Buchwald synthesis reaction Methods 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 102100025752 CASP8 and FADD-like apoptosis regulator Human genes 0.000 description 1
- 108091007924 CK1γ Proteins 0.000 description 1
- 101100115215 Caenorhabditis elegans cul-2 gene Proteins 0.000 description 1
- 101100121123 Caenorhabditis elegans gap-1 gene Proteins 0.000 description 1
- 101100464197 Caenorhabditis elegans pak-1 gene Proteins 0.000 description 1
- 101100014158 Caenorhabditis elegans rack-1 gene Proteins 0.000 description 1
- 102100021535 Calcium/calmodulin-dependent protein kinase kinase 1 Human genes 0.000 description 1
- 102100021534 Calcium/calmodulin-dependent protein kinase kinase 2 Human genes 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 102000004018 Caspase 6 Human genes 0.000 description 1
- 108090000425 Caspase 6 Proteins 0.000 description 1
- 108090000567 Caspase 7 Proteins 0.000 description 1
- 102100029855 Caspase-3 Human genes 0.000 description 1
- 102100038902 Caspase-7 Human genes 0.000 description 1
- 102100026550 Caspase-9 Human genes 0.000 description 1
- 108090000566 Caspase-9 Proteins 0.000 description 1
- 102000016362 Catenins Human genes 0.000 description 1
- 108010067316 Catenins Proteins 0.000 description 1
- 101150066912 Cbl gene Proteins 0.000 description 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
- 101800001299 Cerebellin Proteins 0.000 description 1
- 102400001244 Cerebellin Human genes 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010088874 Cullin 1 Proteins 0.000 description 1
- 102100039195 Cullin-1 Human genes 0.000 description 1
- 102100025525 Cullin-5 Human genes 0.000 description 1
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 1
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 1
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 102000003910 Cyclin D Human genes 0.000 description 1
- 108090000259 Cyclin D Proteins 0.000 description 1
- 102000003909 Cyclin E Human genes 0.000 description 1
- 108090000257 Cyclin E Proteins 0.000 description 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 description 1
- 102000009508 Cyclin-Dependent Kinase Inhibitor p16 Human genes 0.000 description 1
- 102000009506 Cyclin-Dependent Kinase Inhibitor p19 Human genes 0.000 description 1
- 108010009361 Cyclin-Dependent Kinase Inhibitor p19 Proteins 0.000 description 1
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 1
- 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 description 1
- 102100033233 Cyclin-dependent kinase inhibitor 1B Human genes 0.000 description 1
- 101100077740 Cyprinus carpio map2k2 gene Proteins 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 102100021122 DNA damage-binding protein 2 Human genes 0.000 description 1
- 102100033189 Diablo IAP-binding mitochondrial protein Human genes 0.000 description 1
- 101710101225 Diablo IAP-binding mitochondrial protein Proteins 0.000 description 1
- 101710155964 Diuretic hormone 1 Proteins 0.000 description 1
- 101100401560 Drosophila melanogaster mib1 gene Proteins 0.000 description 1
- 101100457919 Drosophila melanogaster stg gene Proteins 0.000 description 1
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 1
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 1
- 102100023266 Dual specificity mitogen-activated protein kinase kinase 2 Human genes 0.000 description 1
- 101710146529 Dual specificity mitogen-activated protein kinase kinase 2 Proteins 0.000 description 1
- 102100023275 Dual specificity mitogen-activated protein kinase kinase 3 Human genes 0.000 description 1
- 102100023401 Dual specificity mitogen-activated protein kinase kinase 6 Human genes 0.000 description 1
- 102100040844 Dual specificity protein kinase CLK2 Human genes 0.000 description 1
- 102100027274 Dual specificity protein phosphatase 6 Human genes 0.000 description 1
- 101710132800 Dual specificity protein phosphatase 6 Proteins 0.000 description 1
- 102100036492 Dual specificity testis-specific protein kinase 1 Human genes 0.000 description 1
- 102100028554 Dual specificity tyrosine-phosphorylation-regulated kinase 1A Human genes 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102100032917 E3 SUMO-protein ligase CBX4 Human genes 0.000 description 1
- 102100035989 E3 SUMO-protein ligase PIAS1 Human genes 0.000 description 1
- 102100036254 E3 SUMO-protein ligase PIAS2 Human genes 0.000 description 1
- 102100030837 E3 SUMO-protein ligase PIAS3 Human genes 0.000 description 1
- 102100030987 E3 SUMO-protein ligase PIAS4 Human genes 0.000 description 1
- 102100037334 E3 ubiquitin-protein ligase CHIP Human genes 0.000 description 1
- 102100027325 E3 ubiquitin-protein ligase HACE1 Human genes 0.000 description 1
- 102100034677 E3 ubiquitin-protein ligase HECTD1 Human genes 0.000 description 1
- 102100034678 E3 ubiquitin-protein ligase HECTD3 Human genes 0.000 description 1
- 102100034674 E3 ubiquitin-protein ligase HECW1 Human genes 0.000 description 1
- 102100034675 E3 ubiquitin-protein ligase HECW2 Human genes 0.000 description 1
- 102100034745 E3 ubiquitin-protein ligase HERC2 Human genes 0.000 description 1
- 102100034893 E3 ubiquitin-protein ligase HUWE1 Human genes 0.000 description 1
- 102100030370 E3 ubiquitin-protein ligase Hakai Human genes 0.000 description 1
- 102100033334 E3 ubiquitin-protein ligase Itchy homolog Human genes 0.000 description 1
- 102100023196 E3 ubiquitin-protein ligase MARCHF8 Human genes 0.000 description 1
- 102100022183 E3 ubiquitin-protein ligase MIB1 Human genes 0.000 description 1
- 102100022199 E3 ubiquitin-protein ligase MIB2 Human genes 0.000 description 1
- 102100035493 E3 ubiquitin-protein ligase NEDD4-like Human genes 0.000 description 1
- 102100023877 E3 ubiquitin-protein ligase RBX1 Human genes 0.000 description 1
- 101710095156 E3 ubiquitin-protein ligase RBX1 Proteins 0.000 description 1
- 102100037964 E3 ubiquitin-protein ligase RING2 Human genes 0.000 description 1
- 102100034189 E3 ubiquitin-protein ligase RNF14 Human genes 0.000 description 1
- 101710109262 E3 ubiquitin-protein ligase RNF31 Proteins 0.000 description 1
- 102100021820 E3 ubiquitin-protein ligase RNF4 Human genes 0.000 description 1
- 102100026245 E3 ubiquitin-protein ligase RNF43 Human genes 0.000 description 1
- 102100038631 E3 ubiquitin-protein ligase SMURF1 Human genes 0.000 description 1
- 102100023431 E3 ubiquitin-protein ligase TRIM21 Human genes 0.000 description 1
- 102100029503 E3 ubiquitin-protein ligase TRIM32 Human genes 0.000 description 1
- 101710164910 E3 ubiquitin-protein ligase TRIM63 Proteins 0.000 description 1
- 102100028093 E3 ubiquitin-protein ligase TRIP12 Human genes 0.000 description 1
- 102100037460 E3 ubiquitin-protein ligase Topors Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102100039563 ETS translocation variant 1 Human genes 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 102100030013 Endoribonuclease Human genes 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- IWNWLPUNKAYUAW-UHFFFAOYSA-N Ethylendiamine dihydroiodide Chemical compound I.I.NCCN IWNWLPUNKAYUAW-UHFFFAOYSA-N 0.000 description 1
- 108010066805 F-Box Proteins Proteins 0.000 description 1
- 102000018700 F-Box Proteins Human genes 0.000 description 1
- 102100038000 F-box only protein 15 Human genes 0.000 description 1
- 101710105178 F-box/WD repeat-containing protein 7 Proteins 0.000 description 1
- 102100028138 F-box/WD repeat-containing protein 7 Human genes 0.000 description 1
- 102100026693 FAS-associated death domain protein Human genes 0.000 description 1
- 108091007133 FBXO15 Proteins 0.000 description 1
- 108010009306 Forkhead Box Protein O1 Proteins 0.000 description 1
- 102000001267 GSK3 Human genes 0.000 description 1
- 108060006662 GSK3 Proteins 0.000 description 1
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 description 1
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 1
- 102100033067 Growth factor receptor-bound protein 2 Human genes 0.000 description 1
- 208000017891 HER2 positive breast carcinoma Diseases 0.000 description 1
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 1
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 108090000353 Histone deacetylase Proteins 0.000 description 1
- 102100038720 Histone deacetylase 9 Human genes 0.000 description 1
- 102100032822 Homeodomain-interacting protein kinase 1 Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 description 1
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 1
- 101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000734668 Homo sapiens Astrocytic phosphoprotein PEA-15 Proteins 0.000 description 1
- 101000896157 Homo sapiens Baculoviral IAP repeat-containing protein 2 Proteins 0.000 description 1
- 101000794028 Homo sapiens Bromodomain testis-specific protein Proteins 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101000914211 Homo sapiens CASP8 and FADD-like apoptosis regulator Proteins 0.000 description 1
- 101000971625 Homo sapiens Calcium/calmodulin-dependent protein kinase kinase 1 Proteins 0.000 description 1
- 101000856414 Homo sapiens Cullin-5 Proteins 0.000 description 1
- 101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 description 1
- 101000944361 Homo sapiens Cyclin-dependent kinase inhibitor 1B Proteins 0.000 description 1
- 101000980932 Homo sapiens Cyclin-dependent kinase inhibitor 2A Proteins 0.000 description 1
- 101001041466 Homo sapiens DNA damage-binding protein 2 Proteins 0.000 description 1
- 101001115394 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 3 Proteins 0.000 description 1
- 101000624426 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 6 Proteins 0.000 description 1
- 101000749291 Homo sapiens Dual specificity protein kinase CLK2 Proteins 0.000 description 1
- 101000714159 Homo sapiens Dual specificity testis-specific protein kinase 1 Proteins 0.000 description 1
- 101000838016 Homo sapiens Dual specificity tyrosine-phosphorylation-regulated kinase 1A Proteins 0.000 description 1
- 101000797579 Homo sapiens E3 SUMO-protein ligase CBX4 Proteins 0.000 description 1
- 101001074629 Homo sapiens E3 SUMO-protein ligase PIAS2 Proteins 0.000 description 1
- 101000583444 Homo sapiens E3 SUMO-protein ligase PIAS3 Proteins 0.000 description 1
- 101000583450 Homo sapiens E3 SUMO-protein ligase PIAS4 Proteins 0.000 description 1
- 101000879619 Homo sapiens E3 ubiquitin-protein ligase CHIP Proteins 0.000 description 1
- 101001009246 Homo sapiens E3 ubiquitin-protein ligase HACE1 Proteins 0.000 description 1
- 101000872880 Homo sapiens E3 ubiquitin-protein ligase HECTD1 Proteins 0.000 description 1
- 101000872865 Homo sapiens E3 ubiquitin-protein ligase HECTD3 Proteins 0.000 description 1
- 101000872869 Homo sapiens E3 ubiquitin-protein ligase HECW1 Proteins 0.000 description 1
- 101000872871 Homo sapiens E3 ubiquitin-protein ligase HECW2 Proteins 0.000 description 1
- 101000872516 Homo sapiens E3 ubiquitin-protein ligase HERC2 Proteins 0.000 description 1
- 101001019732 Homo sapiens E3 ubiquitin-protein ligase HUWE1 Proteins 0.000 description 1
- 101001083405 Homo sapiens E3 ubiquitin-protein ligase Hakai Proteins 0.000 description 1
- 101000997630 Homo sapiens E3 ubiquitin-protein ligase Itchy homolog Proteins 0.000 description 1
- 101000978729 Homo sapiens E3 ubiquitin-protein ligase MARCHF8 Proteins 0.000 description 1
- 101000973503 Homo sapiens E3 ubiquitin-protein ligase MIB1 Proteins 0.000 description 1
- 101000973495 Homo sapiens E3 ubiquitin-protein ligase MIB2 Proteins 0.000 description 1
- 101001023703 Homo sapiens E3 ubiquitin-protein ligase NEDD4-like Proteins 0.000 description 1
- 101001095815 Homo sapiens E3 ubiquitin-protein ligase RING2 Proteins 0.000 description 1
- 101000712013 Homo sapiens E3 ubiquitin-protein ligase RNF14 Proteins 0.000 description 1
- 101000670537 Homo sapiens E3 ubiquitin-protein ligase RNF168 Proteins 0.000 description 1
- 101001103583 Homo sapiens E3 ubiquitin-protein ligase RNF31 Proteins 0.000 description 1
- 101001107086 Homo sapiens E3 ubiquitin-protein ligase RNF4 Proteins 0.000 description 1
- 101000692702 Homo sapiens E3 ubiquitin-protein ligase RNF43 Proteins 0.000 description 1
- 101001107071 Homo sapiens E3 ubiquitin-protein ligase RNF8 Proteins 0.000 description 1
- 101000664993 Homo sapiens E3 ubiquitin-protein ligase SMURF1 Proteins 0.000 description 1
- 101000685877 Homo sapiens E3 ubiquitin-protein ligase TRIM21 Proteins 0.000 description 1
- 101000634982 Homo sapiens E3 ubiquitin-protein ligase TRIM32 Proteins 0.000 description 1
- 101000830231 Homo sapiens E3 ubiquitin-protein ligase TRIM63 Proteins 0.000 description 1
- 101000662670 Homo sapiens E3 ubiquitin-protein ligase Topors Proteins 0.000 description 1
- 101000802406 Homo sapiens E3 ubiquitin-protein ligase ZNRF3 Proteins 0.000 description 1
- 101000813729 Homo sapiens ETS translocation variant 1 Proteins 0.000 description 1
- 101001010783 Homo sapiens Endoribonuclease Proteins 0.000 description 1
- 101000911074 Homo sapiens FAS-associated death domain protein Proteins 0.000 description 1
- 101000878536 Homo sapiens Focal adhesion kinase 1 Proteins 0.000 description 1
- 101000871017 Homo sapiens Growth factor receptor-bound protein 2 Proteins 0.000 description 1
- 101001066404 Homo sapiens Homeodomain-interacting protein kinase 1 Proteins 0.000 description 1
- 101000777670 Homo sapiens Hsp90 co-chaperone Cdc37 Proteins 0.000 description 1
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 description 1
- 101000977771 Homo sapiens Interleukin-1 receptor-associated kinase 4 Proteins 0.000 description 1
- 101000578774 Homo sapiens MAP kinase-activated protein kinase 5 Proteins 0.000 description 1
- 101001059429 Homo sapiens MAP/microtubule affinity-regulating kinase 3 Proteins 0.000 description 1
- 101000588130 Homo sapiens Microsomal triglyceride transfer protein large subunit Proteins 0.000 description 1
- 101000573441 Homo sapiens Misshapen-like kinase 1 Proteins 0.000 description 1
- 101000950695 Homo sapiens Mitogen-activated protein kinase 8 Proteins 0.000 description 1
- 101001018196 Homo sapiens Mitogen-activated protein kinase kinase kinase 5 Proteins 0.000 description 1
- 101001055085 Homo sapiens Mitogen-activated protein kinase kinase kinase 9 Proteins 0.000 description 1
- 101001059991 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 1 Proteins 0.000 description 1
- 101001059989 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 3 Proteins 0.000 description 1
- 101001059982 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 5 Proteins 0.000 description 1
- 101000973157 Homo sapiens NEDD4 family-interacting protein 1 Proteins 0.000 description 1
- 101000650158 Homo sapiens NEDD4-like E3 ubiquitin-protein ligase WWP1 Proteins 0.000 description 1
- 101000650160 Homo sapiens NEDD4-like E3 ubiquitin-protein ligase WWP2 Proteins 0.000 description 1
- 101000970023 Homo sapiens NUAK family SNF1-like kinase 1 Proteins 0.000 description 1
- 101000866795 Homo sapiens Non-histone chromosomal protein HMG-14 Proteins 0.000 description 1
- 101000809045 Homo sapiens Nucleolar transcription factor 1 Proteins 0.000 description 1
- 101000598781 Homo sapiens Oxidative stress-responsive serine-rich protein 1 Proteins 0.000 description 1
- 101000945272 Homo sapiens Phosphorylase b kinase regulatory subunit alpha, liver isoform Proteins 0.000 description 1
- 101001126417 Homo sapiens Platelet-derived growth factor receptor alpha Proteins 0.000 description 1
- 101000872170 Homo sapiens Polycomb complex protein BMI-1 Proteins 0.000 description 1
- 101001125496 Homo sapiens Pre-mRNA-processing factor 19 Proteins 0.000 description 1
- 101000872882 Homo sapiens Probable E3 ubiquitin-protein ligase HECTD2 Proteins 0.000 description 1
- 101000872514 Homo sapiens Probable E3 ubiquitin-protein ligase HERC1 Proteins 0.000 description 1
- 101001035260 Homo sapiens Probable E3 ubiquitin-protein ligase HERC3 Proteins 0.000 description 1
- 101001035259 Homo sapiens Probable E3 ubiquitin-protein ligase HERC4 Proteins 0.000 description 1
- 101000702559 Homo sapiens Probable global transcription activator SNF2L2 Proteins 0.000 description 1
- 101000941994 Homo sapiens Protein cereblon Proteins 0.000 description 1
- 101000613717 Homo sapiens Protein odd-skipped-related 1 Proteins 0.000 description 1
- 101000878540 Homo sapiens Protein-tyrosine kinase 2-beta Proteins 0.000 description 1
- 101000606502 Homo sapiens Protein-tyrosine kinase 6 Proteins 0.000 description 1
- 101000574242 Homo sapiens RING-type E3 ubiquitin-protein ligase PPIL2 Proteins 0.000 description 1
- 101000619506 Homo sapiens Ragulator complex protein LAMTOR2 Proteins 0.000 description 1
- 101000669921 Homo sapiens Rho-associated protein kinase 2 Proteins 0.000 description 1
- 101000944909 Homo sapiens Ribosomal protein S6 kinase alpha-1 Proteins 0.000 description 1
- 101000945096 Homo sapiens Ribosomal protein S6 kinase alpha-5 Proteins 0.000 description 1
- 101000825399 Homo sapiens SHC-transforming protein 1 Proteins 0.000 description 1
- 101000826081 Homo sapiens SRSF protein kinase 1 Proteins 0.000 description 1
- 101000880439 Homo sapiens Serine/threonine-protein kinase 3 Proteins 0.000 description 1
- 101000701396 Homo sapiens Serine/threonine-protein kinase 33 Proteins 0.000 description 1
- 101000695043 Homo sapiens Serine/threonine-protein kinase BRSK1 Proteins 0.000 description 1
- 101000794043 Homo sapiens Serine/threonine-protein kinase BRSK2 Proteins 0.000 description 1
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 description 1
- 101001026870 Homo sapiens Serine/threonine-protein kinase D1 Proteins 0.000 description 1
- 101000691459 Homo sapiens Serine/threonine-protein kinase N2 Proteins 0.000 description 1
- 101001098464 Homo sapiens Serine/threonine-protein kinase OSR1 Proteins 0.000 description 1
- 101000709250 Homo sapiens Serine/threonine-protein kinase SIK2 Proteins 0.000 description 1
- 101000838579 Homo sapiens Serine/threonine-protein kinase TAO1 Proteins 0.000 description 1
- 101000838578 Homo sapiens Serine/threonine-protein kinase TAO2 Proteins 0.000 description 1
- 101000665442 Homo sapiens Serine/threonine-protein kinase TBK1 Proteins 0.000 description 1
- 101000637839 Homo sapiens Serine/threonine-protein kinase tousled-like 1 Proteins 0.000 description 1
- 101000759314 Homo sapiens Tau-tubulin kinase 1 Proteins 0.000 description 1
- 101000772231 Homo sapiens Testis-specific serine/threonine-protein kinase 1 Proteins 0.000 description 1
- 101000753286 Homo sapiens Transcription intermediary factor 1-beta Proteins 0.000 description 1
- 101000850748 Homo sapiens Tumor necrosis factor receptor type 1-associated DEATH domain protein Proteins 0.000 description 1
- 101000733249 Homo sapiens Tumor suppressor ARF Proteins 0.000 description 1
- 101000823316 Homo sapiens Tyrosine-protein kinase ABL1 Proteins 0.000 description 1
- 101000864342 Homo sapiens Tyrosine-protein kinase BTK Proteins 0.000 description 1
- 101000820294 Homo sapiens Tyrosine-protein kinase Yes Proteins 0.000 description 1
- 101000818543 Homo sapiens Tyrosine-protein kinase ZAP-70 Proteins 0.000 description 1
- 101000836268 Homo sapiens U4/U6.U5 tri-snRNP-associated protein 1 Proteins 0.000 description 1
- 101100155061 Homo sapiens UBE3A gene Proteins 0.000 description 1
- 101000808654 Homo sapiens Ubiquitin conjugation factor E4 A Proteins 0.000 description 1
- 101000809046 Homo sapiens Ubiquitin conjugation factor E4 B Proteins 0.000 description 1
- 101000772955 Homo sapiens Ubiquitin-protein ligase E3B Proteins 0.000 description 1
- 101000772964 Homo sapiens Ubiquitin-protein ligase E3C Proteins 0.000 description 1
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 1
- 101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 description 1
- 101150117869 Hras gene Proteins 0.000 description 1
- 102100031568 Hsp90 co-chaperone Cdc37 Human genes 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 description 1
- 102000055031 Inhibitor of Apoptosis Proteins Human genes 0.000 description 1
- 102100039137 Insulin receptor-related protein Human genes 0.000 description 1
- 102100023533 Interleukin-1 receptor-associated kinase 4 Human genes 0.000 description 1
- 108091082332 JAK family Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 102100023424 Kinesin-like protein KIF2C Human genes 0.000 description 1
- 101710134369 Kinesin-like protein KIF2C Proteins 0.000 description 1
- 102100020880 Kit ligand Human genes 0.000 description 1
- 101150105104 Kras gene Proteins 0.000 description 1
- 101150028321 Lck gene Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 102100034069 MAP kinase-activated protein kinase 2 Human genes 0.000 description 1
- 101710141394 MAP kinase-activated protein kinase 2 Proteins 0.000 description 1
- 102100028396 MAP kinase-activated protein kinase 5 Human genes 0.000 description 1
- 102100028920 MAP/microtubule affinity-regulating kinase 3 Human genes 0.000 description 1
- 101150018665 MAPK3 gene Proteins 0.000 description 1
- 101150043871 MAPK7 gene Proteins 0.000 description 1
- 101150024075 Mapk1 gene Proteins 0.000 description 1
- 101710087103 Melittin Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102100026287 Misshapen-like kinase 1 Human genes 0.000 description 1
- 102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 description 1
- 102100033127 Mitogen-activated protein kinase kinase kinase 5 Human genes 0.000 description 1
- 102100026909 Mitogen-activated protein kinase kinase kinase 9 Human genes 0.000 description 1
- 102100028199 Mitogen-activated protein kinase kinase kinase kinase 1 Human genes 0.000 description 1
- 102100028193 Mitogen-activated protein kinase kinase kinase kinase 3 Human genes 0.000 description 1
- 102100028195 Mitogen-activated protein kinase kinase kinase kinase 5 Human genes 0.000 description 1
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 description 1
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 description 1
- 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 description 1
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 description 1
- 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 description 1
- 101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 description 1
- 102100030608 Mothers against decapentaplegic homolog 7 Human genes 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 101100381978 Mus musculus Braf gene Proteins 0.000 description 1
- 101100127339 Mus musculus Camkk1 gene Proteins 0.000 description 1
- 101000596402 Mus musculus Neuronal vesicle trafficking-associated protein 1 Proteins 0.000 description 1
- 101100523604 Mus musculus Rassf5 gene Proteins 0.000 description 1
- 101000800539 Mus musculus Translationally-controlled tumor protein Proteins 0.000 description 1
- 101100155062 Mus musculus Ube3a gene Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- NUGPIZCTELGDOS-QHCPKHFHSA-N N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclopentanecarboxamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CC[C@@H](C=1C=NC=CC=1)NC(=O)C1CCCC1)C NUGPIZCTELGDOS-QHCPKHFHSA-N 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- 102100022547 NEDD4 family-interacting protein 1 Human genes 0.000 description 1
- 102100027550 NEDD4-like E3 ubiquitin-protein ligase WWP1 Human genes 0.000 description 1
- 102100027549 NEDD4-like E3 ubiquitin-protein ligase WWP2 Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 101150073096 NRAS gene Proteins 0.000 description 1
- 101150111783 NTRK1 gene Proteins 0.000 description 1
- 102100021732 NUAK family SNF1-like kinase 1 Human genes 0.000 description 1
- 102100031353 Non-histone chromosomal protein HMG-14 Human genes 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 102000012643 PPIL2 Human genes 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 101710161551 Pectate lyase 3 Proteins 0.000 description 1
- 101710124951 Phospholipase C Proteins 0.000 description 1
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 description 1
- 102100033566 Polycomb complex protein BMI-1 Human genes 0.000 description 1
- 102100029522 Pre-mRNA-processing factor 19 Human genes 0.000 description 1
- 102100034648 Probable E3 ubiquitin-protein ligase HECTD2 Human genes 0.000 description 1
- 102100034747 Probable E3 ubiquitin-protein ligase HERC1 Human genes 0.000 description 1
- 102100039910 Probable E3 ubiquitin-protein ligase HERC3 Human genes 0.000 description 1
- 102100039913 Probable E3 ubiquitin-protein ligase HERC4 Human genes 0.000 description 1
- 102100031021 Probable global transcription activator SNF2L2 Human genes 0.000 description 1
- 101710179609 Probable pectin lyase C Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108010038241 Protein Inhibitors of Activated STAT Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 102100024924 Protein kinase C alpha type Human genes 0.000 description 1
- 101710109947 Protein kinase C alpha type Proteins 0.000 description 1
- 102100037787 Protein-tyrosine kinase 2-beta Human genes 0.000 description 1
- 102100039810 Protein-tyrosine kinase 6 Human genes 0.000 description 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 1
- 101710113459 RAC-alpha serine/threonine-protein kinase Proteins 0.000 description 1
- 101710178916 RING-box protein 1 Proteins 0.000 description 1
- 102000004909 RNF168 Human genes 0.000 description 1
- 102000004910 RNF8 Human genes 0.000 description 1
- 102100022154 Ragulator complex protein LAMTOR2 Human genes 0.000 description 1
- 102100033480 Ras-related protein Rab-8A Human genes 0.000 description 1
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
- 108010079933 Receptor-Interacting Protein Serine-Threonine Kinase 2 Proteins 0.000 description 1
- 102100022502 Receptor-interacting serine/threonine-protein kinase 2 Human genes 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 102100039314 Rho-associated protein kinase 2 Human genes 0.000 description 1
- 102100033536 Ribosomal protein S6 kinase alpha-1 Human genes 0.000 description 1
- 102100033645 Ribosomal protein S6 kinase alpha-5 Human genes 0.000 description 1
- 102000000341 S-Phase Kinase-Associated Proteins Human genes 0.000 description 1
- 108010055623 S-Phase Kinase-Associated Proteins Proteins 0.000 description 1
- 102000036366 SCF complex Human genes 0.000 description 1
- 108091007047 SCF complex Proteins 0.000 description 1
- 239000012722 SDS sample buffer Substances 0.000 description 1
- 102100027720 SH2 domain-containing protein 1A Human genes 0.000 description 1
- 101700026522 SMAD7 Proteins 0.000 description 1
- 102000001332 SRC Human genes 0.000 description 1
- 102100023010 SRSF protein kinase 1 Human genes 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 101000781972 Schizosaccharomyces pombe (strain 972 / ATCC 24843) Protein wos2 Proteins 0.000 description 1
- 102100026758 Serine/threonine-protein kinase 16 Human genes 0.000 description 1
- 102100037628 Serine/threonine-protein kinase 3 Human genes 0.000 description 1
- 102100030515 Serine/threonine-protein kinase 33 Human genes 0.000 description 1
- 102100028623 Serine/threonine-protein kinase BRSK1 Human genes 0.000 description 1
- 102100029891 Serine/threonine-protein kinase BRSK2 Human genes 0.000 description 1
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 description 1
- 102100037310 Serine/threonine-protein kinase D1 Human genes 0.000 description 1
- 102100026180 Serine/threonine-protein kinase N2 Human genes 0.000 description 1
- 102100037143 Serine/threonine-protein kinase OSR1 Human genes 0.000 description 1
- 102100031463 Serine/threonine-protein kinase PLK1 Human genes 0.000 description 1
- 102100034377 Serine/threonine-protein kinase SIK2 Human genes 0.000 description 1
- 102100026715 Serine/threonine-protein kinase STK11 Human genes 0.000 description 1
- 101710181599 Serine/threonine-protein kinase STK11 Proteins 0.000 description 1
- 102100028948 Serine/threonine-protein kinase TAO1 Human genes 0.000 description 1
- 102100038192 Serine/threonine-protein kinase TBK1 Human genes 0.000 description 1
- 102100039988 Serine/threonine-protein kinase ULK1 Human genes 0.000 description 1
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 1
- 102100032015 Serine/threonine-protein kinase tousled-like 1 Human genes 0.000 description 1
- 108010045517 Serum Amyloid P-Component Proteins 0.000 description 1
- 101150082971 Sgk1 gene Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 101000959868 Solanum tuberosum Aspartic protease inhibitor 8 Proteins 0.000 description 1
- 101150108263 Stk16 gene Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 102100033456 TGF-beta receptor type-1 Human genes 0.000 description 1
- 108090000925 TNF receptor-associated factor 2 Proteins 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 102100034779 TRAF family member-associated NF-kappa-B activator Human genes 0.000 description 1
- 108091007076 TRIP12 Proteins 0.000 description 1
- 102100023277 Tau-tubulin kinase 1 Human genes 0.000 description 1
- 102100029350 Testis-specific serine/threonine-protein kinase 1 Human genes 0.000 description 1
- 101001009610 Toxoplasma gondii Dense granule protein 5 Proteins 0.000 description 1
- 102100040250 Transcription elongation factor A protein-like 1 Human genes 0.000 description 1
- 102100022012 Transcription intermediary factor 1-beta Human genes 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 108010011702 Transforming Growth Factor-beta Type I Receptor Proteins 0.000 description 1
- 108010047933 Tumor Necrosis Factor alpha-Induced Protein 3 Proteins 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 102100024596 Tumor necrosis factor alpha-induced protein 3 Human genes 0.000 description 1
- 102100033081 Tumor necrosis factor receptor type 1-associated DEATH domain protein Human genes 0.000 description 1
- 102100033254 Tumor suppressor ARF Human genes 0.000 description 1
- 102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 description 1
- 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 description 1
- 102100021788 Tyrosine-protein kinase Yes Human genes 0.000 description 1
- 102100021125 Tyrosine-protein kinase ZAP-70 Human genes 0.000 description 1
- 102100027244 U4/U6.U5 tri-snRNP-associated protein 1 Human genes 0.000 description 1
- 102000056723 UBE3C Human genes 0.000 description 1
- 102100038532 Ubiquitin conjugation factor E4 A Human genes 0.000 description 1
- 102100038487 Ubiquitin conjugation factor E4 B Human genes 0.000 description 1
- 102000018478 Ubiquitin-Activating Enzymes Human genes 0.000 description 1
- 108010091546 Ubiquitin-Activating Enzymes Proteins 0.000 description 1
- 102000003431 Ubiquitin-Conjugating Enzyme Human genes 0.000 description 1
- 108060008747 Ubiquitin-Conjugating Enzyme Proteins 0.000 description 1
- 102100030429 Ubiquitin-protein ligase E3B Human genes 0.000 description 1
- 108010005705 Ubiquitinated Proteins Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 102000013814 Wnt Human genes 0.000 description 1
- 108050003627 Wnt Proteins 0.000 description 1
- 101001001642 Xenopus laevis Serine/threonine-protein kinase pim-3 Proteins 0.000 description 1
- 102000006083 ZNRF3 Human genes 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 108700000707 bcl-2-Associated X Proteins 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229940125763 bromodomain inhibitor Drugs 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- QNEFNFIKZWUAEQ-UHFFFAOYSA-N carbonic acid;potassium Chemical compound [K].OC(O)=O QNEFNFIKZWUAEQ-UHFFFAOYSA-N 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 101150069072 cdc25 gene Proteins 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 102000022604 damaged DNA binding proteins Human genes 0.000 description 1
- 108091013406 damaged DNA binding proteins Proteins 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 description 1
- 230000006195 histone acetylation Effects 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 108010054372 insulin receptor-related receptor Proteins 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 101150069838 mapk-15 gene Proteins 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910001507 metal halide Inorganic materials 0.000 description 1
- 150000005309 metal halides Chemical group 0.000 description 1
- 239000003697 methyltransferase inhibitor Substances 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- JTSLALYXYSRPGW-UHFFFAOYSA-N n-[5-(4-cyanophenyl)-1h-pyrrolo[2,3-b]pyridin-3-yl]pyridine-3-carboxamide Chemical compound C=1C=CN=CC=1C(=O)NC(C1=C2)=CNC1=NC=C2C1=CC=C(C#N)C=C1 JTSLALYXYSRPGW-UHFFFAOYSA-N 0.000 description 1
- 230000017095 negative regulation of cell growth Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 108010056274 polo-like kinase 1 Proteins 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001023 pro-angiogenic effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000004063 proteosomal degradation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 108010014186 ras Proteins Proteins 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 108010087686 src-Family Kinases Proteins 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- VULKFBHOEKTQSF-UHFFFAOYSA-N tert-butyl n-[2-(2-aminoethoxy)ethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCOCCN VULKFBHOEKTQSF-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 102100035070 von Hippel-Lindau disease tumor suppressor Human genes 0.000 description 1
- 239000012130 whole-cell lysate Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
本發明係關於一種具有式Ab-[L1
-(A-L2
-B)m
]n
之免疫複合體,其中:(a)Ab係抗體或其結合片段;(b)L1
及L2
各自獨立地係連接鏈基團,其中L1
及L2
相同或不同,並且其中L1
連接鏈鍵結至L2
;(c)A係靶蛋白配位體/結合物;(d)B係泛素連接酶配位體/結合物,且(e)n及m獨立地係1至8之整數。靶蛋白包括激酶、G蛋白偶聯受體、轉錄因子、磷酸酶及RAS超家族成員。
Description
本發明係關於基於ADC及PROTAC技術之新穎治療劑。
抗體長期以來一直係基礎研究以及醫學用途中不可或缺之工具,因為其對靶抗原具有高度特異性及親和力。抗體之一個關鍵特徵係其高特異性及其結合靶抗原之能力,對其進行標記以便利用補體依賴性細胞毒性(CDC)或抗體依賴性細胞介導之細胞毒性(ADCC)去毒殺標的細胞。抗體亦可藉由結合靶抗原且抑制靶抗原之功能而賦予治療益處。然而,許多針對腫瘤特異性抗原之未修飾抗體通常缺乏治療活性。儘管一些抗體可以成功地應用作導向導彈,以抗體藥物複合體(ADC)提供有效之細胞毒性藥物,但許多ADC具有有限的治療潛力並且可能需要進一步改良。
蛋白水解靶向嵌合體(pro
teolysista
rgetingc
himera,PROTAC)係一種雙頭分子,能夠藉由選擇性誘導細胞內蛋白水解來除去不需要之蛋白質。PROTAC由兩個蛋白質結合部分組成,一個用於結合E3泛素連接酶,而另一個用於結合靶蛋白。藉由結合兩種蛋白質,PROTAC將靶蛋白帶至E3連接酶,導致靶蛋白之標記(亦即泛素化),以便於隨後由蛋白酶體降解。
泛素化涉及三個主要步驟:活化、共軛及連接,分別由泛素活化酶(E1)、泛素共軛酶(E2)及泛素連接酶(E3)進行。此連續級聯之結果係將泛素與靶蛋白共價結合。泛素化之蛋白質最終會由蛋白酶體降解。
PROTAC技術於2001年首次被描述(Sakamoto等人,「Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation」,Proceedings of the National Academy of Sciences of the United States of America
.98
(15): 8554-9)。自彼時起,此技術已被用於幾種藥物設計:pVHL、MDM2、β-TrCP1、小腦蛋白(cereblon)及c-IAP1。雖然這些現有技術的PROTAC藥物非常有用,但仍需要更好的PROTAC藥物。
本發明之實施例係關於分支抗體-PROTAC複合體(APC)。本發明之分支抗體-PROTAC複合體結合了ADC及PROTAC兩種方法之優點,並且與直線型式的APC相比,分支型式的APC在開發或加工中具有若干益處。在本發明之分支抗體-PROTAC複合體中,習知ADC中之有效負載(藥物)經PROTAC置換並鍵結至PROTAC分子之連接鏈基團部分。此等新治療劑之選擇性高,毒性低,使用更安全,且活體內半衰期更長。
本發明之一個態樣係關於免疫複合體。根據本發明之一個實施例的免疫複合體具有式(I):Ab-[L2
-(A-L1
-B)m
]n
,其中:(a)Ab係抗體或其結合片段;(b)L1
及L2
各自獨立地係連接鏈基團,其中L1
及L2
可以相同或不同;(c)A係靶蛋白配位體/結合物;(d)B係泛素連接酶配位體/結合物,且(e)n及m各自獨立地係1至8之整數。
根據本發明之一些實施例,靶蛋白可以係激酶、G蛋白偶聯受體、轉錄因子、磷酸酶及RAS超家族成員。
藉由以下描述及所包括的附圖,本發明之其他態樣將變得顯而易見。APC及分支之結構
本發明之實施例係關於分支APC。分支APC經由PROTAC之連接鏈基團部分將抗體與PROTAC鍵結。本發明之分支APC可以被視為抗體-藥物複合體(ADC)之類似物,其中習知ADC中之有效負載(藥物)經PROTAC置換,PROTAC經由PROTAC中之連接鏈基團與抗體共軛。亦即,在本發明之分支APC中,抗體(或其結合片段)經由連接鏈基團(L2
)與PROTAC經由PROTAC之連接鏈基團部分(L1
)共價鍵結,而非經由靶蛋白結合部分(A)或泛素連接酶結合物(B)鍵結。抗體上之共價連接鏈可以在蛋白質部分(例如,恆定區或可變區)上或在碳水化合物(糖部分)上。
圖1顯示說明直線型APC與分支APC之間的差異之示意圖。分支APC優於直線型APC之優點可能包括以下各項:
1.維持PROTAC部分中之靶配位體(A)及E3連接酶配位體(B)之原始結構,使得A及B的結合親和力不會改變,因為抗體連接於PROTAC部分中之連接鏈基團(L1
),而非連接在PROTAC部分之任一端(A或B)。
2.連接基團在連接鏈基團上之結構修飾比在配位體(A或B)上之修飾容易得多,並且兩個連接鏈基團部分(L1
及L2
)之間的連接更靈活。
3. 連接鏈基團之修飾適用於大多數APC。因此,可以設計連接鏈基團以使用共同的鍵結官能基,使得不同的抗體部分可以容易地與相同的PROTAC鍵結,或者相同的抗體可以容易地與不同的PROTAC鍵結。
根據本發明實施例之分支APC可以用下式(I)表示:,
其中:
(a)Ab係抗體或其結合片段;
(b)L1
及L2
獨立地係連接鏈基團,其中L1
係PROTAC部分內之連接鏈基團(亦即PROTAC = A-L1
-B),且L2
係經由PROTAC之連接鏈基團部分(L1
)鍵結抗體與PROTAC之連接鏈基團;
(c)A係靶配位體/結合物(亦即,靶蛋白之結合物,該靶蛋白可以係激酶、G蛋白偶聯受體、轉錄因子、磷酸酶、RAS超家族成員等);
(d)B係泛素連接酶配位體/結合物,其中泛素連接酶可以係E2或E3泛素連接酶,且
(e)n及m獨立地係1至8之整數。
本發明之分支APC結合ADC及PROTAC兩者之優點,並代表一類新的治療劑。術語「分支」係指上式(I)中所示之結構,其中抗體-L2
連接鏈基團與PROTAC中之L1
連接鏈基團鍵結。其中抗體-L2
連接鏈基團連接至PROTAC之任一末端(A或B)的其他類型的APC將稱為「非分支的」或「直線型的」。此等新的分支APC的選擇性高,活體內半衰期長,治療窗口大,適用性廣,且使用更安全。此外,此等分支APC比非分支(直線型)APC更容易合成。
抗體-藥物複合體(ADC)係一類治療劑,其中藥物(或有效負載)與抗體或其抗原結合片段連接。ADC中之抗體與選定的靶(通常係細胞上之靶)結合,藉此將藥物帶至靶附近,從而產生高選擇性的治療效果。ADC之實例可以係靶向癌細胞上表現之蛋白質的抗體,並且有效負載可以係細胞毒性劑(例如紫杉醇)。
由於存在抗體,ADC係大分子,分子量通常為約150 KDa或更高。因此,腎臟過濾不會消除ADC。此外,抗體恆定區包括與腎中受體相互作用之位點,其可以將抗體運送且再循環回至循環中。因此,抗體之活體內半衰期長,通常為數週。此外,抗體可以容易地被細胞內化,使得有效負載極有效地傳遞至細胞中。由於ADC具有特異性及長效性,因此其係有前景的治療劑。然而,ADC之作用依賴於有效負載,其並不像催化劑一樣起作用。因此,需要足夠量的有效負載來殺死或抑制靶蛋白或細胞。過量的有效負載可能會導致毒性。
PROTAC由兩個蛋白質結合部分組成,一個用於結合E3泛素連接酶,而另一個用於結合靶蛋白。PROTAC可以結合其靶蛋白並將其帶至E3泛素連接酶。在三級複合物形成後,E3泛素連接酶將泛素轉移至靶蛋白之表面離胺酸,產生泛素化之靶蛋白,其註定要由蛋白酶體機制降解。泛素化後,PROTAC經釋放並繼續尋找用於泛素化及降解之靶蛋白。因此,PROTAC像催化劑一樣起作用,且少量的PROTAC可以取得實質性的結果。
在上式(I)中,A組分係與欲降解之靶蛋白結合之基團。A組分可包括特異性結合於靶蛋白之任何部分。以下係小分子靶蛋白結合部分之非限制性實例:Hsp90抑制劑、激酶抑制劑、MDM2抑制劑、靶向含人類BET溴結構域(Bromodomain)之蛋白質的化合物、HDAC抑制劑、人類離胺酸甲基轉移酶抑制劑、血管生成抑制劑、免疫抑制化合物及靶向芳基烴受體(AHR)之化合物等。下面描述之組合物舉例說明此等類型的小分子靶蛋白結合部分之一些成員。此種小分子靶蛋白結合部分亦包括此等組合物之醫藥學上可接受之鹽、對映異構體、溶劑合物及多晶型物,以及可以靶向所關注蛋白質之其他小分子。
通常,靶蛋白可包括例如結構蛋白、受體、酶、細胞表面蛋白、與細胞功能相關之蛋白質等。因此,ADC-PROTAC之A組分可以係結合蛋白質靶之任何肽或小分子,諸如FoxOl、HDAC、DP-1、E2F、ABL、AMPK、BRK、BRSK I、BRSK2、BTK、CAMKK1、CAMKK α、CAMKK β、Rb、Suv39HI、SCF、p19INK4D、GSK-3、pi8 INK4、myc、細胞週期素E、CDK2、CDK9、CDG4/6、環素D、pl6 INK4A、cdc25A、BMI1、SCF、Akt、CHK1/2、C 1 δ、CK1 γ、C 2、CLK2、CSK、DDR2、DYRK1A/2/3、EF2K、EPH-A2/A4/B 1/B2/B3/B4、EIF2A 3、Smad2、Smad3、Smad4、Smad7、p53、p21 Cipl、PAX、Fyn、CAS、C3G、SOS、Tal、Raptor、RACK-1、CRK、Rapl、Rac、KRas、NRas、HRas、GRB2、FAK、PI3K、spred、Spry、mTOR、MPK、LKBl、PAK 1/2/4/5/6、PDGFRA、PYK2、Src、SRPK1、PLC、PKC、PKA、PKB α/β、PKC α/γ/ζ、PKD、PLKl、PRAK、PRK2、WAVE-2、TSC2、DAPKI、BAD、IMP、C-TAK1、TAKl、TAOl、TBK1、TESK1、TGFBR1、TIE2、TLK1、TrkA、TSSK1、TTBK1/2、TTK、Tpl2/cotl、MEK1、MEK2、PLDL Erk1、Erk2、Erk5、Erk8、p90RSK、PEA-15、SRF、p27 KIP1、TIF la、HMGN1、ER81、MKP-3、c-Fos、FGF-R1、GCK、GSK3 β、HER4、HIPK1/2/3/、IGF-1R、cdc25、UBF、LAMTOR2、Statl、StaO、CREB、JAK、Src、PTEN、NF-κ B、HECTH9、Bax、HSP70、HSP90、Apaf-1、Cyto c、BCL-2、Bcl-xL、Smac、XIAP、凋亡蛋白酶-9、凋亡蛋白酶-3、凋亡蛋白酶-6、凋亡蛋白酶-7、CDC37、TAB、IKK、TRADD、TRAF2、R1P1、FLIP、TAKl、JNK1/2/3、Lck、A-Raf、B-Raf、C-Raf、MOS、MLK1/3、MN 1/2、MSK1、MST2/3/4、MPSK1、MEKKI、ME K4、MEL、ASK1、MINK1、MKK 1/2/3/4/6/7、NE 2a/6/7、NUAK1、OSR1、SAP、STK33、Syk、Lyn、PDK1、PHK、PIM 1/2/3、Ataxin-1、mTORCl、MDM2、p21 Wafl、細胞週期素Dl、Lamln A、Tpl2、Myc、連環蛋白、Wnt、IKK-β、IKK-γ、IKK-α、IKK-ε、ELK、p65RelA、IRAKI、IRA 2、IRAK4、IRR、FADD、TRAF6、TRAF3、MKK3、MKK6、ROCK2、RSK1/2、SGK 1、SmMLCK、SIK2/3、ULK1/2、VEGFR1、WNK l、YES1、ZAP70、MAP4K3、MAP4K5、MAPKlb、MAPKAP-K2 K3、p38 α/β/δ/γ MAPK、極光A、極光B、極光C、MCAK、Clip、MAPKAPK、FAK、MARK 1 /2/3/4、Mucl、SHC、CXCR4、Gap-1、Myc、β-連環蛋白/TCF、Cbl、BRM、Mcl-1、BRD2、BRD3、BRD4、AR、RAS、ErbB3、EGFR、IRE1、HPK1、RIPK2及ERct,包括列出的此等靶蛋白之所有變異體、突變、剪接變異體、插入缺失及融合。
B組分係結合E3泛素連接酶之基團。E3泛素連接酶(其中超過600種在人類中已知)賦予受質對泛素化之特異性。存在結合此等連接酶之已知配位體。如本文所述,E3泛素連接酶結合基團可以係可以結合E3泛素連接酶之胜肽或小分子。E3泛素連接酶之實例包括:von Hippel-Lindau (VHL);小腦蛋白、XIAP、E3A;MDM2;後期促進複合物;UBR5 (EDDI);SOCS/BC-box/eloBC/CUL5/RING;LNXp80;CBX4;CBLL1;HACE1;HECTD1;HECTD2;HECTD3;HECW1;HECW2;HERC1;HERC2;HERC3;HERC4;HUWE1;ITCH;NEDD4;NEDD4L;PPIL2;PRPF19;PIAS1;PIAS2;PIAS3;PIAS4;RANBP2;RNF4;RBX1;SMURF1;SMURF2;STUB1;TOPORS;TRIP12;UBE3A;UBE3B;UBE3C;UBE4A;UBE4B;UBOXS;UBR5;WWP1;WWP2;Parkin;A20/TNFAIP3;AMFR/gp78;ARA54;β-TrCPl/BTRC;BRCA1;CBL;CHIP/STUB 1;E6;E6AP/UBE3A;F-盒蛋白15/FBXO15;FBXW7/Cdc4;GRAIL/RNF128;HOIP/RNF31;cIAP-1/HIAP-2;cIAP-2/HIAP-1;cIAP (pan);ITCH/AIP4;KAP1;MARCH8、智能彈(Mind Bomb)1/MIB1;智能彈2/MIB2;MuRF1/TRIM63;NDFIP1;NEDD4;NleL;Parkin;RNF2;RNF4;RNF8;RNF168;RNF43;SART1;Skp2;SMURF2;TRAF-1;TRAF-2;TRAF-3;TRAF-4;TRAF-5;TRAF-6;TRIMS;TRIM21;TRIM32;UBR5;及ZNRF3。
例示性E3泛素連接酶係von Hippel-Lindau(VHL)腫瘤抑制因子,其係E3連接酶複合物VCB-Cul2之受質識別次單元。VCCB-Cul2複合物由VHL、延伸蛋白(elongin)B及C、Cul2及Rbx1組成。VHL之主要受質係缺氧誘導因子let(HIF-let),其係轉錄因子,響應於低氧水準而上調基因,諸如促血管生成生長因子VEGF及誘生紅血球之細胞激素紅血球生成素。結合VHL之化合物可以係羥脯胺酸化合物,諸如WO2013/106643中揭示之彼等,以及US2016/0045607、WO2014187777、US20140356322及US 9,249,153中描述之其他化合物。
另一種例示性E3泛素連接酶係小腦蛋白。小腦蛋白係一種蛋白質,其與受損DNA結合蛋白1(DDB1)、Cullin-4A(CUL4A)及cullin 1調節劑(ROC 1)形成E3泛素連接酶複合物。此種複合物使許多其他蛋白質泛素化。小腦蛋白靶蛋白之泛素化導致纖維母細胞生長因子8(FGF8)及纖維母細胞生長因子10(FGF10)之含量增加。FGF8又調節許多發育過程,例如肢體及聽囊形成。在沒有小腦蛋白之情況下,DDB1與DDB2形成複合物,作為DNA損傷結合蛋白之用。已知沙利度胺(thalidomide)、來那度胺(lenalidomide)、泊馬度胺(pomalidomide)及其類似物與小腦蛋白結合。結合小腦蛋白之其他小分子化合物亦係已知的,例如US2016/0058872及US2015/0291562中揭示之化合物。此外,鄰苯二甲醯亞胺與結合物(例如BET溴結構域之拮抗劑)之共軛可以為PROTAC提供高選擇性的依賴於小腦蛋白之BET蛋白質降解。Winter等人,Science
, 2015年6月19日, 第1376頁。此等PROTAC可以與本文所述的抗體共軛以形成APC。
PROTAC之特異性依賴於其靶配位體結合靶蛋白以便降解之。若特異性不高,則此可能導致脫靶效應(副作用)。此外,PROTAC通常係小分子(MW約1000)。其依賴於擴散進入細胞,效率較低(特別在分子量約為1000之情況下)。此外,因為其係小分子,由於腎臟過濾通常活體內半衰期較短。因此,可能需要以更高的給藥頻率給予PROTAC。
本發明之抗體-PROTAC複合體(APC)在大小上與抗體或ADC相似,其活體內半衰期較長。因此,本發明之APC亦具有較長的活體內半衰期(例如,數週),並且由於抗體的存在可以藉由內化作用進入細胞。此外,APC具有雙重選擇性:一種來自抗體,而另一種來自PROTAC中之靶蛋白結合物。例如,本發明之APC中的抗體可以結合癌細胞上之特定抗原,接著APC藉由內化進入細胞。一旦進入細胞,PROTAC部分中之靶蛋白結合物就會找到靶蛋白並將其帶至E3泛素連接酶中進行泛素化。泛素化的靶蛋白經過標記以便由蛋白酶體降解。因此,本發明之APC之選擇性高並且副作用較少。
此外,本發明之APC具有催化作用模式之優點,類似於PROTAC。因此,APC之治療有效劑量可以更低,並且由於其更長的活體內半衰期,其可以以更低的頻率給予。此等性質使得本發明之APC更具特異性且使用更安全。
因此,APC形式係新穎的並且代表有希望的新治療劑方法。此方法通常可應用於與任何病症相關之任何靶蛋白。(參見Crews等人,「Proteolysis-Targeting Chimeras: Induced Protein Degradation as a Therapeutic Strategy」,ACS Chem. Biol
.2017
,12
(4), 892-898)。
本發明之實施例可以應用於引起疾病或病症之任何靶蛋白,藉由獲得抗體且接著使用該抗體與PROTAC鍵結(亦即與E3泛素連接酶配位體或抑制劑鍵結之靶蛋白結合物)。抗體針對在含有靶蛋白之細胞上表現之抗原。PROTAC中之靶蛋白結合物將視所靶向之蛋白質而定。例如,對於靶酶(例如激酶),可以設計抑制劑作為配位體/結合物。
Nutlin衍生物結合MDM2(雙微2同源物;亦稱為E3泛素-蛋白質連接酶Mdm2),其係p53腫瘤抑制因子的負調節子。Mdm2具有作為識別p53腫瘤抑制因子之N端反式活化結構域(TAD)之E3泛素連接酶及作為p53轉錄活化抑制劑的功能。貝他定(bestatin)(烏苯美司(ubenimex))接合cIAP1(凋亡蛋白-1之細胞抑制劑)。IMiD沙利度胺及其衍生物泊馬度胺(pomalidomide)及來那度胺(lenalidomide)結合小腦蛋白。
以下描述使用特定實例來說明本發明之實施例。該等實例使用溴結構域及末端外結構域(BET)蛋白家族作為靶蛋白,並使用曲妥珠單抗(trastuzumab)作為抗體。然而,在此等實施例中使用之任何特定的BET抑制劑、泛素連接酶3抑制劑及曲妥珠單抗僅用於說明,且不應解釋為限制本發明之範疇。熟習此項技術者將理解,在不脫離本發明之範疇的情況下,其他修改及變化係可能的。
溴結構域及末端外結構域(BET)蛋白家族,包括BRD2、BRD3及BRD4,藉由控制組蛋白乙醯化依賴性染色質複合物之組裝而在許多細胞過程中發揮關鍵作用,包括發炎基因表現、有絲分裂及病毒/宿主相互作用。BET蛋白之抑制劑可逆地結合溴結構域或BET蛋白:BRD2、BRD3、BRD4及BRDT。其可以阻止BET蛋白與乙醯化組蛋白及轉錄因子之間的蛋白質-蛋白質相互作用。因此,BET抑制劑具有抗癌、免疫抑制及其他作用。在APC中使用BET抑制劑將靶向BET家族蛋白質進行泛素化,藉此引起蛋白酶體消除BET家族蛋白質。
以下描述本發明之一些實施例之細節。然而,此等細節僅用於說明,並且熟習此項技術者將理解,在不脫離本發明之範疇的情況下,其他修改及變化係可能的。
實例1:曲妥珠單抗-BRD4-PROTAC-1之製備化合物 2
之合成
在此實例中,BET抑制劑係OTX015,其係可口服生物可利用的BRD2、BRD3及BRD4之小分子抑制劑(EC50
= 10至19 nM)。OTX015下調c-Myc表現並誘導細胞週期停滯及細胞凋亡。因此,其對多種實體腫瘤及白血病具有抗增殖作用。
化合物 2 :
向OTX015(1)
(0.2 mmol)及1-溴-2-(2-溴乙氧基)乙烷(1 mmol)於二甲基甲醯胺(5 mL)中之混合物中添加碳酸鉀(0.6 mmol)。將混合物在50℃下攪拌24小時。反應完成後,反應混合物用二氯甲烷及水萃取。接著,有機層用飽和食鹽水洗並經無水硫酸鎂乾燥。減壓除去有機溶劑。藉由管柱層析用甲醇:二氯甲烷(1:19)純化殘餘物,得到黃色固體化合物 2
(58%產率)。1
H NMR (600 MHz, 氯仿-d
) : δ 7.45 (d,J
= 9.1 Hz, 2H), 7.38 (d,J
= 8.6 Hz, 2H), 7.28 (d,J
= 8.6 Hz, 2H), 6.78 (d,J
= 9.1 Hz, 2H), 4.71 (dd,J
= 8.0, 6.2 Hz, 1H), 4.06 (dd,J
= 5.4, 4.5 Hz, 2H), 3.86 - 3.82 (m, 4H), 3.78 (dd,J
= 14.5, 8.0 Hz, 1H), 3.57 (dd,J
= 14.5, 6.2 Hz, 1H), 3.47 (t,J
= 6.2 Hz, 2H), 2.66 (s, 3H), 2.38 (d,J
= 0.6 Hz, 3H), 1.65 (d,J
= 0.6 Hz, 3H)。LCMS (ESI): m/z [C33
H37
ClN6
O4
S+H]+
之計算值642.08, 實驗值642.52 [M+H]+
。化合物 4
之合成
化合物 4 :
向泊馬度胺(3
)(0.2 mmol)及(2-(2-胺基乙氧基)乙基)胺基甲酸第三丁酯(0.22 mmol)於DMF(5 mL)中之溶液中添加N,N-二異丙基乙胺(0.4 mmol)。將反應混合物在90℃下攪拌12小時。反應完成後,反應混合物用二氯甲烷及水萃取。接著,有機層用飽和食鹽水洗並經無水硫酸鎂乾燥。減壓除去有機溶劑。在急驟管柱上用乙酸乙酯:己烷(2:3)純化後,將黃色殘餘物溶於二氯甲烷中,且添加三氟乙酸(1 mL)。將混合物在室溫下攪拌0.5小時。之後,反應混合物用二氯甲烷及水萃取。接著,有機層用飽和食鹽水洗並經無水硫酸鎂乾燥。減壓除去有機溶劑。殘餘物藉由管柱層析用甲醇:二氯甲烷(1:9)純化,得到黃色固體化合物 4
。1
H NMR (600 MHz, 氯仿-d
) δ 7.35 (t, J = 7.8 Hz, 1H), 6.93 (d, J = 7.0 Hz, 1H), 6.78 (d, J = 8.6 Hz, 1H), 6.38 (d, J = 5.1 Hz, 1H), 4.81 (dd, J = 11.6, 5.1 Hz, 1H), 3.62 (d, J = 4.0 Hz, 2H), 3.56 (d, J = 4.5 Hz, 2H), 3.33 (d, J = 4.1 Hz, 2H), 3.05 - 3.04 (m, 2H), 2.71 - 2.53 (m, 3H), 2.01 - 1.93 (m, 1H)。LCMS (ESI): m/z [C33
H37
ClN6
O4
S+H]+
之計算值361.14, 實驗值361.22 [M+H]+
。化合物 5
之合成
化合物 5
:向化合物 2
(0.2 mmol)、化合物 4
(0.6 mmol)及碘化鉀(0.2 mmol)於乙腈/二甲基甲醯胺(3:1,4 mL)中之溶液中添加碳酸鉀(0.6 mmol)。將反應混合物在50℃下攪拌72小時。反應完成後,反應混合物用二氯甲烷及水萃取。接著,有機層用飽和食鹽水洗並經無水硫酸鎂乾燥。減壓除去有機溶劑。藉由管柱層析用甲醇:二氯甲烷(1:12)純化殘餘物,得到黃色固體化合物 5
(19.7%產率)。1
H NMR (600 MHz, 氯仿-d
) δ 7.53 - 7.36 (m, 5H), 7.36 - 7.29 (m, 2H), 7.09 (dd,J
= 7.0, 3.7 Hz, 1H), 6.88 (d,J
= 8.7 Hz, 1H), 6.82 (dd,J
= 8.7, 1.4 Hz, 2H), 4.89 (dt,J
= 12.5, 6.1 Hz, 1H), 4.66 (ddd,J
= 7.9, 6.0, 3.5 Hz, 1H), 4.10 - 4.02 (m, 2H), 3.84 - 3.58 (m, 9H), 3.55 - 3.41 (m, 2H), 3.41 - 3.30 (m, 2H), 3.02 - 2.91 (m, 3H), 2.87 - 2.68 (m, 3H), 2.67 (s, 3H), 2.40 (s, 3H), 2.10 - 2.07 (m, 1H), 1.67 (s, 3H)。LCMS (ESI): m/z [C33
H37
ClN6
O4
S+H]+
之計算值922.30, 實驗值922.49 [M+H]+
。化合物 7
之合成
化合物 7
:向化合物 5
(0.2 mmol)及Mal-C5-VC-PAB-PNP化合物 6
(0.2 mmol)於二甲基甲醯胺(5 mL)中之溶液中添加羥基苯并三唑(0.4 mmol)及吡啶(0.4 mmol)。將反應混合物在室溫下攪拌72小時。反應完成後,反應混合物用二氯甲烷及水萃取。接著,有機層用飽和食鹽水洗並經無水硫酸鎂乾燥。減壓除去有機溶劑。藉由管柱層析用甲醇:二氯甲烷(1:16)純化殘餘物,得到黃色固體化合物 7
(46.3%產率)。1
H NMR (600 MHz, 氯仿-d
) δ 7.55 - 7.40 (m, 7H), 7.33 (d,J
= 7.2 Hz, 2H), 7.25 - 7.19 (m, 2H), 7.08 (d,J
= 7.0 Hz, 1H), 6.92 - 6.83 (m, 1H), 6.79 - 6.68 (m, 2H), 6.68 - 6.65 (m, 2H), 5.07 - 5.00 (m, 2H), 4.77 - 4.71 (m, 1H), 4.71 - 4.60 (m, 1H), 4.37 - 4.29 (m, 1H), 4.04 - 3.96 (m, 1H), 3.93 - 3.85 (m, 1H), 3.77 - 3.34 (m, 21H), 3.28 - 3.14 (m, 1H), 3.11 - 3.02 (m, 1H), 2.93 - 2.71 (m, 3H), 2.69 (s, 3H), 2.42 (s, 3H), 2.04 - 2.01 (m, 1H), 1.91 - 1.81 (m, 2H), 1.77 - 1.70 (m, 1H), 1.69 (s, 3H), 1.62 - 1.54 (m, 4H), 1.33 - 1.25 (m, 5H), 0.91 - 0.87 (m, 6H)。LCMS (ESI): m/z [C33
H37
ClN6
O4
S+H]+
之計算值1520.58, 實驗值1521.14 [M+H]+
。
曲妥珠單抗-BRD4-PROTAC1
之鍵結
向曲妥珠單抗1 mg(5.0 mg/mL)於緩衝液(25 mM硼酸鈉pH 8,0.025 M NaCl,1 mM二亞乙基三胺五乙酸(DTPA))中之溶液中用參(2-羧乙基)膦(TCEP,4.0莫耳當量)在37℃下處理2小時。過量的TCEP使用Amicon Ultra-15離心過濾裝置使用含30 kDa NMWL之緩衝液(25 mM硼酸鈉pH 8,0.025 M NaCl,1 mM DTPA)移除,接著用化合物 7
(20莫耳當量)在25℃下處理4小時。將反應混合物以使用含30 kDa NMWL之pH7.4 PBS緩衝液的Amicon Ultra-15離心過濾裝置中止並濃縮,得到曲妥珠單抗-BRD4-PROTAC1
。
實例2:曲妥珠單抗-BRD4-PROTAC-2
之製備化合物 8
之合成
化合物 8 :
向4-(N-順丁烯二醯亞胺甲基)環己烷-1-甲酸丁二醯亞胺(SMCC)(0.75 mmol)於乙腈(7 mL)中之溶液中添加1,2-乙二硫醇(0.82 mmol)。將反應混合物在室溫下攪拌3小時。反應完成後,反應混合物用二氯甲烷及水萃取。接著,有機層用飽和食鹽水洗並經無水硫酸鎂乾燥。減壓除去有機溶劑。將殘餘物藉由管柱層析用乙酸乙酯:己烷(3:2)純化,得到白色固體化合物 8
(34.8%產率)。化合物 9
之合成
化合物 9
:向化合物 7
(0.02 mmol)於乙腈/二甲基甲醯胺(1:1,6 mL)中之溶液中添加化合物 8
(0.04 mmol)。將反應混合物在室溫下攪拌16小時。反應完成後,反應混合物用二氯甲烷及水萃取。接著,有機層用飽和食鹽水洗並經無水硫酸鎂乾燥。減壓除去有機溶劑。藉由管柱層析用乙酸乙酯:己烷(3:2)純化殘餘物,得到黃色固體化合物 9
(86.2%產率)。
曲妥珠單抗-BRD4-PROTAC2
之鍵結
向曲妥珠單抗1 mg(5.0 mg/mL)於緩衝液(50 mM磷酸鉀、50 mM氯化鈉、2 mM EDTA;pH 6.5)中之溶液中緩慢添加30當量的9
(5 mM於DMSO中)。將反應混合物在37℃下攪拌18小時。使用Amicon Ultra-15離心過濾裝置使用含30 kDa NMWL之pH 7.4 PBS緩衝液脫鹽並濃縮抗體製備物,得到曲妥珠單抗-BRD4-PROTAC2
。
如上所述,本發明之APC具有分支型式,其中抗體-L2
連接鏈基團與PROTAC中之L1
連接鏈基團連接。如上述實例中所示,L2
連接鏈基團與L1
連接鏈基團之連接不會改變PROTAC之A結合物或B結合物,並且連接反應相對容易。作為比較,以下實例說明合成直線型(非分支)APC之嘗試,其中L2
連接鏈基團與A結合物或B結合物鍵結。
實例3:直線型式之BRD4-PROTAC之合成(17)
圖4說明可能的經由ARV-825之A結合物連接鏈合成之合成流程。蛋白質配位體或連接酶結合物之官能基修飾並不容易。此外,並非所有蛋白質配位體或連接酶結合物皆具有合適的供修飾用之功能基團。在此實施例中,OTX015(PROTAC ARV-825之蛋白質配位體)上之氯原子難以轉化為另一種官能基,諸如胺基。OTX015或ARV-825在布赫瓦爾德(Buchwald)反應(鈀催化之偶合反應)及烏爾曼(Ullman)反應(銅催化之偶合反應)下顯示無反應性。嚴苛的反應條件,諸如金屬鹵化物交換,將導致化合物分解。根據文獻(EP1887008A1),應該在一開始就引入不同的BRD4抑制劑官能基。換言之,將連接鏈基團與蛋白質配位體或連接酶結合物直接鍵結將使合成更複雜。
相比之下,如本發明揭示之分支連接鏈基團策略提供了連接任何蛋白質配位體或連接酶結合物以形成具有以下優點之APC的新方法。APC維持靶蛋白配位體及E3連接酶配位體之結構,且因此結合親和力不會改變。連接基團在連接鏈基團上之結構修飾比在配位體上容易得多。連接鏈基團上之修飾適用於大多數PROTAC,並且可以為不同的PROTAC設計「共同的」鍵結官能基,使得相同的抗體可以與不同的PROTAC鍵結,或者相同的PROTAC可以與不同的抗體鍵結。
實例4:生物活性
測試各種式(I)之免疫複合體降解靶向蛋白的特異性及能力。以下描述不同分析之簡要描述。
西方墨點(Western blot)
評估式(I)化合物在BRD4蛋白質降解中之細胞效力。溴結構域蛋白4(BRD4)係BET(溴結構域及末端外)家族蛋白之一,並且涉及血液惡性腫瘤及實體腫瘤之腫瘤發生。BRD4識別並結合乙醯化組蛋白,並跨及細胞分裂及轉錄調節之表觀遺傳記憶傳遞中起關鍵作用。靶向BRD4之有效抑制劑顯示出抗腫瘤活性,抑制各種癌細胞之增殖及轉化。此導致BRD4成為癌症治療之有希望的治療靶。已經顯示BRD4蛋白水解靶向嵌合體(PROTAC)藉由誘導BRD4蛋白質降解而具有抗癌活性。然而,除了抗癌作用外,正常細胞亦受此等藥劑之影響。此導致了BET抑制之令人擔憂的副作用,諸如自閉症樣症候群及對記憶形成之損害。
在本發明中,產生具有分支型式之BRD4-PROTAC抗體複合體,以保持BRD4-PROTAC模態之完整性,增強癌細胞靶向之特異性,並減少潛在的脫靶效應。「BRD4-PROTAC」係指包括BRD4蛋白之靶結合物的PROTAC。藉由將「BRD4-PROTAC」與識別癌細胞上之抗原的抗體鍵結。抗體之高特異性允許所得的複合體(亦即Ab-BRD4-PROTAC)靶向特定的癌細胞並對健康細胞產生較小的毒性。例如,抗體可以係曲妥珠單抗,且癌細胞可以係HER2陽性BT-474乳癌細胞。經由西方墨點分析在細胞BRD4蛋白質降解中測試各種式(I)化合物(亦即,具有不同BRD4結合物、不同E3結合物及/或不同抗體)。以下使用曲妥珠單抗鍵結之BRD4-PROTAC來說明本發明實施例之益處。
對於西方墨點實驗,HER2陽性BT-474及HER2陰性MDA-MB-231乳癌細胞分別在具有10% FBS之DMEM及L15培養基中培養,並培養隔夜。在分析當天,用每種測試化合物預處理二十萬個細胞24小時。24小時後,藉由添加2×SDS樣品緩衝液收穫全細胞裂解物。蛋白質藉由SDS-PAGE電泳分離並轉移至PVDF膜。根據標準方案使用各種初級抗體及二級抗體進行免疫墨點來偵測蛋白質表現。抗BRD4之抗體及抗兔IgG、HRP鍵結之二級抗體係購自Cell Signaling Technology(Danvers,MA)。抗肌動蛋白之抗體係購自Millipore(Burlington, MA)。免疫墨點藉由化學發光(SuperSignal™ West Femto Maximum Sensitivity Substrate, Thermo Fisher, Waltham, MA)顯示,並藉由ChemiDocTM
MP成像系統(Bio-Rad, Hercules, CA)偵測。西方墨點之條帶強度亦藉由ChemiDocTM
MP成像系統定量。將對應於藥物處理組之條帶之相對強度與未治療組之相對強度進行比較。
圖2顯示分析結果。ARV-825(CAS編號1818885-28-7)係異雙功能分子,其包含與E3連接酶小腦蛋白結合部分連結鏈之BRD4結合部分。ARV-825係蛋白水解靶向嵌合體(PROTAC)。(參見Lu, J.等人, 「Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4」,Chem. Biol.
22(6), 755-763 (2015))。本發明化合物 5
係ARV-825之分支型式。本發明化合物 7
係具有另外的溶酶體可切除的二肽(纈胺酸-瓜胺酸) 連結鏈基團之化合物 5
。
如圖2所示,在此細胞培養分析中,化合物 5
與ARV-825一樣有效促進BRD4之降解。相比之下,化合物 7
不能在高達1 μM之化合物 7
處理時降解BRD4蛋白質,此可能係由於纈胺酸-瓜胺酸二肽導致較低的滲透性所引起的。此結果表明,若APC在進入細胞之前過早地被切除,則釋放的PROTAC(例如,化合物 7
)將不會引起脫靶效應。因此,本發明之APC將具有更高的安全界限。
圖3顯示化合物 7
曲妥珠單抗抗體複合體(亦即實例1)在HER2陽性BT-474乳癌細胞而非HER2陰性MDA-MB-231乳癌細胞中表現出特異性BRD4蛋白降解活性。此種APC不會引起AKT蛋白或肌動蛋白之降解。此表明PROTAC中抗體與連結鏈基團之分支鍵結不會損害PROTAC之活性。重要的是,在活體內情況下,抗體(曲妥珠單抗)將APC引導至表現特定抗原(例如HER2)之彼等細胞,藉此減少脫靶效應。因此,實例1在臨床應用中與AV-825一樣有效但更安全。
此等結果表明,本發明之抗體複合體(分支APC)可以增強癌細胞靶向之特異性,強制細胞攝取PROTAC模態,並減少潛在的脫靶效應。另外,若抗體過早分離,則釋放的PROTAC(例如化合物 7
)由於纈胺酸-瓜胺酸二肽而具有相對較低的滲透性,並且不會引起不希望的脫靶效應,產生較高安全裕度。
抗增殖活性
如上所述,本發明之APC可用於治療攜帶特定抗原之疾病或病症。此等疾病可以係癌症、自體免疫疾病、感染性疾病或血管增生性病症。癌症可能係肺癌、結腸癌、結直腸癌、乳癌、前列腺癌、肝癌、胰臟癌、膀胱癌、胃癌、腎癌、唾液腺癌、卵巢癌、子宮體癌、宮頸癌、口腔癌、皮膚癌、腦癌、淋巴瘤或白血病。本發明之APC對細胞生長之抑制藉由CellTiterTM
-96分析法量測。在具有不同HER2表現表型之乳癌細胞株中評估APC之細胞毒性。結果顯示本發明之APC僅對HER2陽性乳癌細胞有毒,其中BRD4蛋白、Src激酶或RAS蛋白可藉由使用與曲妥珠單抗鍵結的適當PROTAC而經特異性靶向以便蛋白酶體降解。
本發明之APC係有前景的新治療劑,因為其具有ADC及PROTAC之優點。此外,本發明之分支型APC顯示出優於直線型ADC PROAC之優點,並且可用於治療攜帶特定抗原之病症。
本發明之一些實施例涉及使用本發明之APC治療疾病或病症之方法。該疾病可能係癌症。癌症之具體實例可包括乳癌、胃癌、鱗狀細胞癌、結腸癌及表現特定抗原之白血病。APC中使用之抗體可以係曲妥珠單抗、西妥昔單抗(cetuximab)、利妥昔單抗(rituximab)、本妥昔單抗(brentuximab)、吉妥珠單抗(gemtuzumab)、伊珠單抗(inotuzumab)、薩希珠單抗(sacituzumab)、阿侖單抗(alemtuzumab)、尼妥珠單抗(nimotuzumab)。APC之具體實例可以係分支曲妥珠單抗鍵結之PROTAC,用於靶向具有HER2表現之乳癌或胃癌。
分支抗體鍵結之PROTAC可以以不同的形式合成,諸如不同的連結鏈基團或不同的抗體共軛方法。化合物 18
及化合物 19
係顯示用於離胺酸共軛之不同連結鏈基團形式之實例。化合物 18
及化合物 19
中PROTAC之合成遵循與具有PEG連結鏈基團之化合物 9
相同的方法。化合物 18
及化合物 19
可以用與上述實例2相同的方法合成。具有PEG連結鏈基團之分支PROTAC可以實現更好的溶解度及與抗體的共軛。
已經用有限數量的實例說明本發明之實施例。熟習此項技術者將理解,在不脫離本發明之範疇的情況下,其他修改及變化係可能的。因此,保護範疇應僅受所附申請專利範圍之限制。
圖1顯示說明直線型(非分支)APC之結構及分支APC之結構的示意圖。
圖2顯示用SDS-PAGE電泳及西方墨點分析,在BT-474乳癌細胞培養物中,各種濃度的ARV-825及本發明化合物 5
(但並非本發明化合物 7
)促進BRD4降解之作用。ARV-825係已知的小分子的靶向BRD4之PROTAC。本發明化合物 5
係ARV-825之分支型式。結果顯示化合物 5
具有與ARV-825對BRD4相當的降解活性。相比之下,本發明化合物 7
,其係具有另外的溶酶體可切除的二肽(纈胺酸-瓜胺酸)之化合物 5
,在高達1 μM的化合物 7
處理時不能降解BRD4蛋白。此結果可能源於以下事實:由於纈胺酸-瓜胺酸二肽而具有相對較低滲透性之化合物 7
不能有效地內化至細胞中。BRD4及AKT標記BRD4及AKT條帶之位置,且肌動蛋白用作加載對照。
圖3顯示實例1在HER2陽性BT-474乳癌細胞而非HER2陰性MDA-MB-231乳癌細胞中表現出特異性BRD4蛋白質降解活性。實例1係分支曲妥珠單抗-化合物 7
免疫複合體(亦即,具有曲妥珠單抗作為抗體及化合物 7
作為PROTAC之分支APC)。此外,此種分支APC不會引起AKT蛋白或肌動蛋白之降解。
圖4顯示藉由經ARV-825中之A結合物鍵結的直線型APC之合成流程。
Claims (13)
- 如請求項1之免疫複合體,其中該靶蛋白選自由以下組成之群:激酶、G蛋白偶聯受體、轉錄因子、磷酸酶及RAS超家族成員。
- 如請求項1之免疫複合體,其中A選自由以下組成之群:熱休克蛋白90(HSP90)抑制劑、激酶或磷酸酶抑制劑、MDM2抑制劑、HDAC抑制劑、人類離胺酸甲基轉移酶抑制劑、血管生成抑制劑、免疫抑制化合物、以及靶向以下各者之化合物:含有人類BET溴結構域之蛋白質、芳基烴受體(AHR)、REF受體激酶、FKBP、雄激素受體(AR)、雌激素受體(ER)、甲狀腺激素受體、HIV蛋白酶、HIV整合酶、HCV蛋白酶或醯基蛋白硫酯 酶-1及醯基蛋白硫酯酶-2(APT1及APT2)。
- 如請求項1之免疫複合體,其中B係結合於選自由以下組成之群的E3連接酶之基團:XIAP、VHL、小腦蛋白及MDM2。
- 如請求項1之免疫複合體,其中Ab係單株抗體或其變異體。
- 如請求項1之免疫複合體,其中Ab結合於一或多種選自由以下組成之群的多肽:DLL3、EDAR、CLL1;BMPR1B;E16;STEAP1;0772P;MPF;NaPi2b;Sema 5b;PSCA hlg;ETBR;MSG783;STEAP2;TrpM4;CRIPTO;CD21;CD79b;FcRH2;B7-H4;HER2;NCA;MDP;IL20Rct;短蛋白聚糖(Brevican);EphB2R;ASLG659;PSCA;GEDA;BAFF-R;CD22;CD79a;CXCRS;HLA-DOB;P2X5;CD72;LY64;FcRH1;IRTA2;TENB2;PMEL17;TMEFF1;GDNF-Ral;Ly6E;TMEM46;Ly6G6D;LGR5;RET;LY6K;GPR19;GPR54;ASPHD1;酪胺酸酶;TMEM118;GPR172A;MUC16及CD33。
- 如請求項5之免疫複合體,其中Ab係曲妥珠單抗(trastuzumab)、西妥昔單抗(cetuximab)、利妥昔單抗(rituximab)、本妥昔單抗(brentuximab)、吉妥珠單抗(gemtuzumab)、伊珠單抗(inotuzumab)、薩希珠單抗(sacituzumab)、阿侖單抗(alemtuzumab)或尼妥珠單抗(nimotuzumab)。
- 一種醫藥組合物,其包含如請求項1之免疫複合體及一或多種醫藥學上可接受之賦形劑。
- 一種如請求項1至7中任一項之免疫複合體或如請求項8之醫藥組合物之用途,其係用以製備用於治療攜帶特定抗原並由靶蛋白引起之疾病之藥品,其中該靶蛋白可由該靶蛋白配位體/結合物特異性結合,該特定抗原表現於含有該靶蛋白之細胞上且可由該抗體或其結合片段特異性結合。
- 如請求項9之用途,其中該疾病係癌症。
- 如請求項10之用途,其中該癌症係乳癌或胃癌,並且該Ab係曲妥珠單抗。
- 如請求項10之用途,其中該癌症係結腸癌或鱗狀細胞癌,並且該Ab係西妥昔單抗。
- 如請求項10之用途,其中該疾病係白血病,並且該Ab係利妥昔單抗、本妥昔單抗、吉妥珠單抗、伊珠單抗或阿侖單抗。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862615955P | 2018-01-10 | 2018-01-10 | |
US62/615,955 | 2018-01-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW201938201A TW201938201A (zh) | 2019-10-01 |
TWI759576B true TWI759576B (zh) | 2022-04-01 |
Family
ID=67219830
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW108100998A TWI759576B (zh) | 2018-01-10 | 2019-01-10 | 抗體protac複合體 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20210015942A1 (zh) |
EP (1) | EP3737422A4 (zh) |
JP (2) | JP2021510375A (zh) |
KR (1) | KR20200108289A (zh) |
CN (1) | CN112135637A (zh) |
AU (1) | AU2019206507A1 (zh) |
CA (1) | CA3088059A1 (zh) |
TW (1) | TWI759576B (zh) |
WO (1) | WO2019140003A1 (zh) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10683387B2 (en) | 2016-10-04 | 2020-06-16 | Massachusetts Institute Of Technology | Bottlebrush copolymers and uses thereof |
CN111741769B (zh) * | 2018-04-20 | 2022-09-16 | 四川科伦博泰生物医药股份有限公司 | 一种多功能化合物、其制备方法及其在医药上的应用 |
JPWO2020027225A1 (ja) | 2018-07-31 | 2021-11-11 | ファイメクス株式会社 | 複素環化合物 |
CN111018857B (zh) * | 2018-10-09 | 2023-06-02 | 嘉兴优博生物技术有限公司 | 靶向蛋白酶降解平台(ted) |
WO2020086858A1 (en) * | 2018-10-24 | 2020-04-30 | Genentech, Inc. | Conjugated chemical inducers of degradation and methods of use |
PT116050B (pt) * | 2020-01-09 | 2022-06-15 | Hovione Farm S A | Conjugados fármaco-ligando e inibidores das proteínas da família bromodomínio e domínio extraterminal -(bet) modificados |
US20210220391A1 (en) * | 2020-01-10 | 2021-07-22 | Massachusetts Institute Of Technology | Proteolysis targeting chimeric molecules (protacs) with functional handles and uses thereof |
CN111217804A (zh) * | 2020-02-21 | 2020-06-02 | 四川大学华西医院 | 一种靶向降解ido1的protac化合物及其制备方法和应用 |
GB202007106D0 (en) | 2020-05-14 | 2020-07-01 | Ucl Business Plc | Cyclosporine analogues |
US20230414723A1 (en) * | 2020-10-26 | 2023-12-28 | Trustees Of Tufts College | Enhanced hyt-induced protein degradation using lipid nanoparticle delivery |
AU2022253902A1 (en) | 2021-04-10 | 2023-11-02 | Profoundbio Us Co. | Folr1 binding agents, conjugates thereof and methods of using the same |
CA3216459A1 (en) | 2021-04-23 | 2022-10-27 | Profoundbio Us Co. | Anti-cd70 antibodies, conjugates thereof and methods of using the same |
EP4353736A1 (en) * | 2021-06-11 | 2024-04-17 | Nibec Co., Ltd. | Bio protac protein having intracellular delivery function, and pharmaceutical composition comprising same |
CA3225636A1 (en) | 2021-07-02 | 2023-01-05 | Merck Patent Gmbh | Anti-protac antibodies and complexes |
TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
CN115109047B (zh) * | 2021-09-08 | 2024-02-20 | 中国科学院化学研究所 | 一种基于protac设计的铁死亡诱导剂 |
WO2023056069A1 (en) * | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
CN114288422B (zh) * | 2022-01-21 | 2023-04-28 | 陕西科技大学 | 一种化学靶向降解目标蛋白的脂质体及其制备方法 |
CN114560908A (zh) * | 2022-03-11 | 2022-05-31 | 国家纳米科学中心 | 一种多肽protac分子及其制备方法和应用 |
CN116751199A (zh) * | 2023-06-02 | 2023-09-15 | 中国科学院基础医学与肿瘤研究所(筹) | 一种线粒体蛋白酶靶向嵌合体、制备方法及用途 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102320082B1 (ko) * | 2014-04-14 | 2021-10-29 | 아비나스 오퍼레이션스, 인코포레이티드 | 단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법 |
PL3458101T3 (pl) * | 2016-05-20 | 2021-05-31 | F. Hoffmann-La Roche Ag | Koniugaty PROTAC-przeciwciało i sposoby ich stosowania |
-
2019
- 2019-01-09 US US16/244,090 patent/US20210015942A1/en active Pending
- 2019-01-09 JP JP2020538121A patent/JP2021510375A/ja active Pending
- 2019-01-09 WO PCT/US2019/012931 patent/WO2019140003A1/en unknown
- 2019-01-09 AU AU2019206507A patent/AU2019206507A1/en active Pending
- 2019-01-09 CA CA3088059A patent/CA3088059A1/en active Pending
- 2019-01-09 CN CN201980018480.5A patent/CN112135637A/zh active Pending
- 2019-01-09 KR KR1020207021320A patent/KR20200108289A/ko active Search and Examination
- 2019-01-09 EP EP19738787.1A patent/EP3737422A4/en active Pending
- 2019-01-10 TW TW108100998A patent/TWI759576B/zh active
-
2023
- 2023-11-02 JP JP2023188179A patent/JP2024012491A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2019140003A1 (en) | 2019-07-18 |
US20210015942A1 (en) | 2021-01-21 |
CA3088059A1 (en) | 2019-07-18 |
JP2024012491A (ja) | 2024-01-30 |
AU2019206507A1 (en) | 2020-08-27 |
TW201938201A (zh) | 2019-10-01 |
EP3737422A4 (en) | 2021-10-06 |
KR20200108289A (ko) | 2020-09-17 |
CN112135637A (zh) | 2020-12-25 |
JP2021510375A (ja) | 2021-04-22 |
EP3737422A1 (en) | 2020-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI759576B (zh) | 抗體protac複合體 | |
RU2753416C2 (ru) | Новые конъюгаты аманитина | |
KR101823526B1 (ko) | 유도형질로 활성화되는 다기능성 항암제 전구체, 이의 제조방법 및 이의 용도 | |
Schumacher et al. | Next generation maleimides enable the controlled assembly of antibody–drug conjugates via native disulfide bond bridging | |
CN112752759A (zh) | 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物及其方法与用途 | |
KR20200083605A (ko) | 프로그램가능한 중합체성 약물 | |
WO2015195904A1 (en) | Her2 antibody-drug conjugates | |
WO2018036438A1 (zh) | 一种抗体-药物偶联物及其制备方法和应用 | |
EA027925B1 (ru) | Ендиины, их конъюгаты и способы их получения и применения | |
PT1940789E (pt) | Métodos e compostos para preparar análogos cc-1065 | |
JP2019534889A (ja) | 抗体−ポリマー−薬物コンジュゲート | |
CN111051310A (zh) | 合成鹅膏蕈碱的新方法 | |
EP3145984A1 (en) | Therapeutic conjugates with sulfated dendrimers for intracellular targeting | |
US20230144004A1 (en) | Delta-opioid receptor targeted agent for molecular imaging and immunotherapy of cancer | |
Ma et al. | Non-small molecule PROTACs (NSM-PROTACs): protein degradation kaleidoscope | |
JP2019178158A (ja) | ポリマーリンカーおよびそれらの使用法 | |
EP3242661A1 (en) | Myc g-quadruplex stabilizing small molecules and their use | |
Mandler et al. | Modifications in synthesis strategy improve the yield and efficacy of geldanamycin− herceptin immunoconjugates | |
WO2022218288A1 (zh) | 一种抗体药物偶联物的制备方法 | |
AU2016347606B2 (en) | Bifunctional prodrugs | |
António | Cysteine Functionalization in the Synthesis of Complex and Well-Defined Bioconjugates | |
CN114515339B (zh) | 针对生长抑素受体的多肽偶联药物及其应用 | |
TW202317205A (zh) | 用於癌症治療之經放射性標記之parp抑制劑結合物 | |
Cartwright | The design and synthesis of duocarmycin-based conjugates for targeted delivery to tumours | |
Charoenpattarapreeda | Development of stapled peptide targeted covalent inhibitors and synthesis of novel ADC payloads for applications in cancer therapy |